Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
i 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  A PHASE 1  RANDOMIZED SINGLE ORAL DOSE CROSS -OVER STUDY INVESTIGATING 
DESMETRAMADOL  DOSE PROPORTIONALITY  AND FOOD EFFECT IN NORMAL 
HUMAN SUBJEC TS  
 
Syntrix Protocol O MNI -PAIN -103 
 
Version: 1.2  
11 May 2020  
 
Study Agent:    Desmetramadol  10 mg tablets   
 
Protocol Number:   Syntrix -OMNI -PAIN -103 
 
IND Number:    103,997   
 
Study Site:  Celerion  
 
Principal Investigator :  Robert Schwab , MD  
 
Sponsor:  Syntrix Biosystems, Inc.  
 
Personnel:    Stuart Kahn, MD (Project Director, Sponsor’s Medical Monitor)  
     Aaron Schuler, PhD (Formulation Scientist)  
     John Zebala, MD, PhD (Regulatory Affairs)  
      
     
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
ii 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  Contact Information  
 
Clinical Site  Principal Investigator  
Celerion  
 621 Rose Street  
Lincoln, NE 68502   Robert Schwab  
  
Sponsor  
Syntrix Biosystems, Inc.  
215 Clay Street NW  
Suite B5  
Auburn, WA  98001  
Fax:  253 -833-8127  
Stuart Kahn  
Tel: 206 -524-0214  
Alt Tel: 253 -833-8009 x32  
Mobile: 206 -330-7604   John Zebala  
253-833-8009  
Aaron Schuler  
Tel: 253-833-8009 x21   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
iii 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  Principal Investigator Agreement  
 
Protoc ol Number: Syntrix -Omni -Pain-103 
 
I, the undersigned, have reviewed this protocol, including all attached information.  
 
I agree to conduct this clinical study in accordance with the E6 Guidance o f the International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
“Good Clinical Practice: Consolidated Guidance”, and the U.S. Code of Federal Regulations governing 
the protection of human subject s (21 CFR 50), Institutional Review Boards (21 CFR 56) and the 
obligations of clinical investigators (21 CFR 312). Furthermore, I agree to maintain all study 
documentation for the time specified in this protocol.  
 
 
 
 
Principal Investigator Signature  
 
 
Printed Name  
 
 
 
Date  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
iv 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  Table of Contents  
Contact Information  ................................ ................................ ................................ ................................ ....... ii 
Principal Investigator Agreement  ................................ ................................ ................................ .................  iii 
Table of Contents  ................................ ................................ ................................ ................................ .........  iv 
List of Ab breviations  ................................ ................................ ................................ ................................ ... vii 
Protocol Summary (Synopsis)  ................................ ................................ ................................ ......................  ix 
Schematic of Study Design  ................................ ................................ ................................ .........................  xii 
1 BACKGROUND AND SCIENTIFIC RATIONALE  ................................ ................................ ...........  1 
1.1 Background Information  ................................ ................................ ................................ .................  1 
1.1.1  Tramadol and desmetramadol: Background and Pharmacology  ................................ .............  1 
1.1.2  Unmet Need: Absent Tramadol Efficacy in Patients with Low CYP2D6 Activity  ................  3 
1.1.3  Significant Negative Impact on Patient Care and Safety  ................................ ........................  4 
1.2 Description of the Study Agent  ................................ ................................ ................................ ...... 5 
1.2.1  Pilot Study of Desmetramadol in a Human Subject  ................................ ................................  5 
1.2.2  Phase 1 PK and PD Study in Normal Healthy Volunteers  ................................ ......................  6 
1.3 Rationale  ................................ ................................ ................................ ................................ .........  8 
1.3.1  Overall Study Design  ................................ ................................ ................................ ..............  8 
1.3.2  Dosage  ................................ ................................ ................................ ................................ ..... 9 
1.3.3  Study Population  ................................ ................................ ................................ .....................  9 
1.3.4  Study Endpoints  ................................ ................................ ................................ .......................  9 
1.4 Potential Risks and Benefits  ................................ ................................ ................................ ...........  9 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ........................  10 
3 STUDY DESIGN  ................................ ................................ ................................ ................................ . 10 
3.1 Description of the Study Design  ................................ ................................ ................................ ... 10 
3.2 Study Endpoints  ................................ ................................ ................................ ............................  11 
3.2.1  Primary Endpoint -Pharmacokinetic Responses  ................................ ................................ .... 11 
3.2.2  Secondary Endpoint -Safety  ................................ ................................ ................................ ... 11 
3.3 Study Site  ................................ ................................ ................................ ................................ ...... 12 
4 STUDY POPULATION  ................................ ................................ ................................ ......................  12 
4.1 Subject Inclusion Criteria  ................................ ................................ ................................ .............  12 
4.2 Subject Exclusion Criteria  ................................ ................................ ................................ ............  13 
5 STUDY AGENT/INTERVENTIONS  ................................ ................................ ................................ . 14 
5.1 Study Drug (Desmetramadol)  ................................ ................................ ................................ ....... 14 
5.1.1  Formulation, Packaging, and Labeling  ................................ ................................ ..................  14 
5.1.2  Study Drug Storage and Stability  ................................ ................................ ..........................  14 
5.1.3  Preparation, Administration, and Dosage of Study Drug  ................................ ......................  14 
5.1.4  Study Drug Shipping and Accountability Procedures  ................................ ...........................  15 
5.2 Assessment of Subject Compliance with Study Drug  ................................ ................................ .. 15 
5.3 Concomitant Medications and Procedures  ................................ ................................ ...................  15 
5.4 Precautionary and Prohibited Medications and Procedures  ................................ .........................  15 
5.4.1  Prohibited Medications and Procedures  ................................ ................................ ................  15 
6 STUDY PROCEDURES and EVALUATIONS  ................................ ................................ .................  16 
6.1 Screening (≤ 30 days Before Day -1) and Check -In (Day -1) ................................ .......................  16 
6.2 Randomization and Study Drug Treatment Period 1 (Day 1 Through Day 3).  ............................  16 
6.3 Study Drug Treatment P eriod 2 (Day 4 through Day 6)  ................................ ...............................  17 
6.4 Study Drug Treatment Period 3 (Day 7 through Day 9)  ................................ ...............................  17 
6.5 Study Drug Treatment Period 4 (Day 10 through Day 11)  ................................ ...........................  18 
6.6 Subject Samples  ................................ ................................ ................................ ............................  18 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
v 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  7 ADVERSE EVENTS  ................................ ................................ ................................ ...........................  18 
7.1 Specification of Safety Parameters  ................................ ................................ ...............................  18 
7.2 Definitions  ................................ ................................ ................................ ................................ .... 19 
7.2.1  Adverse Event  ................................ ................................ ................................ .......................  19 
7.2.2  Serious Adverse Event  ................................ ................................ ................................ ..........  19 
7.2.3  Unexpected Adverse Event  ................................ ................................ ................................ ... 19 
7.2.4  Life-Threatening Event  ................................ ................................ ................................ .........  19 
7.3 Assessment of Adverse Events  ................................ ................................ ................................ ..... 19 
7.3.1  Severity Grading  ................................ ................................ ................................ ....................  19 
7.3.2  Definition of Relationship of Adverse Events to Study Drug  ................................ ...............  20 
7.4 Reporting Adverse Events  ................................ ................................ ................................ ............  20 
7.5 Follow -up of Subjects with Adverse Events  ................................ ................................ .................  21 
8 Assessment of Risk  ................................ ................................ ................................ ..............................  21 
8.1 Criteria for Interrupting the Study Based on Dose -Limiting Toxicity  ................................ .........  21 
8.1.1  Rules for Discontinuing Study Drug in an Individual Subject  ................................ ..............  21 
8.1.2  Suspension of the Study  ................................ ................................ ................................ ........  22 
8.1.3  Confirmatory Testing of Significant (grade 3 and 4) Laboratory Abnormalities  .................  22 
8.2 Subject Withdrawal from the Study  ................................ ................................ ..............................  22 
8.3 Replacement of a Subject Who Withdraws from Study Treatment  ................................ ..............  22 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ . 23 
9.1 Randomization Procedures  ................................ ................................ ................................ ...........  23 
9.2 Plan for Statistical Summaries and Analyses  ................................ ................................ ...............  23 
9.2.1  General Consid erations  ................................ ................................ ................................ .........  23 
9.2.2  Disposition of Subjects  ................................ ................................ ................................ ..........  23 
9.2.3  Demographic Characteristics  ................................ ................................ ................................ . 24 
9.2.4  Safety Endpoints  ................................ ................................ ................................ ....................  24 
9.2.5  PK Analysis  ................................ ................................ ................................ ...........................  25 
9.3 Planned Interim Analysis  ................................ ................................ ................................ ..............  25 
9.4 Procedures for Deviations from Planned Statistical Analyses  ................................ ......................  25 
9.5 Appropriate Method and Timing for Analyzing Outcome Measures  ................................ ...........  25 
9.5.1  Methods and Timing for the Primary End -Point  ................................ ................................ ... 25 
9.6 Study Hypotheses  ................................ ................................ ................................ .........................  26 
9.7 Sample Size Considerations  ................................ ................................ ................................ ..........  26 
9.8 Maintenance of Trial Randomization List  ................................ ................................ ....................  28 
9.9 Subject Enrollment a nd Follow -Up ................................ ................................ ..............................  28 
9.10  Safety Review  ................................ ................................ ................................ ...............................  28 
9.11  Final Analysis Plan  ................................ ................................ ................................ .......................  28 
10 ADMINISTRATIVE PROCEDURES  ................................ ................................ .............................  29 
10.1  Institutional Review Board Approval  ................................ ................................ ...........................  29 
10.2  Informed Consent  ................................ ................................ ................................ .........................  29 
10.3  Direct Access to Source Data/Documents, S tudy Monitoring, Data Collection  ..........................  29 
10.4  DATA ANALYSIS  ................................ ................................ ................................ .......................  30 
10.5  Modification of the Protocol  ................................ ................................ ................................ .........  30 
10.6  Protocol Deviation(s)  ................................ ................................ ................................ ....................  30 
10.7  Departure from the Protocol  ................................ ................................ ................................ .........  31 
10.8  Suspension of the Study  ................................ ................................ ................................ ................  31 
10.9  Study Termination by the Sponsor  ................................ ................................ ...............................  31 
10.10  Use of Information and Publications  ................................ ................................ .........................  31 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
vi 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  10.11  Record Retention  ................................ ................................ ................................ .......................  32 
10.12  Exclusion of Minorities, and Children (Special Populations)  ................................ ...................  32 
10.13  Subject Confidentiality  ................................ ................................ ................................ ..............  32 
Appendix A: Schedule of Procedures/Evaluations  ................................ ................................ ......................  33 
Appendix B.  Calculation of Selected Inclusion Criteria  ................................ ................................ ............  35 
Appendix C: Toxicity Grading Scale for Clinical Laboratory Values1 ................................ .......................  36 
Appendix D: Toxicity Grading Scale for Clinical AEs¹  ................................ ................................ ..............  37 
References  ................................ ................................ ................................ ................................ ...................  38 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
vii 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  List of Abbreviations  
 
AE    Adverse Event  
ALT    Alanine Aminotransferase  
ANOVA   Analysis of Variance  
AST    Aspartate Aminotransferase  
API   Active Pharmaceutical Ingredient  
AUC    Area Under the Curve  
AUMC   Area Under the First Moment Curve  
BMI    Body Mass Index  
BP    Blood Pressure  
BPM    Beats Per Minute  
BUN    Blood Urea Nitrogen  
CBC    Complete Blood Count  
CFR    Code Federal Regulations  
CI    Confidence Interval  
CIOMS   Council for International Organizations of Medical Sciences  
CONSORT   Consolidated Standards of Reporting Trials  
CPU    Clinical Pharmacology Unit  
CRF    Case Report Form  
CRO    Contract Research Organization  
CRP    C-Reactive Protein  
Css max   Concentration steady state maximum  
Css min   Concentration steady state minimum  
CYP    Cytochrome P -450 
DLDD    Drug Liking, Drug Disliking  
DSM    Data and Safety Monitoring  
DSMB    Data and Safety Monitoring Board  
ECG    Electrocardiogram  
EM   Extensive metabolizers  
EMA    European Medicines Agency  
FDA    Food and Drug Administration  
FWA    Federal -Wide Assurance  
GCP    Good Clinical Practice  
GLP    Good Laboratory Practice  
GMP    Good Manufacturing  Practice  
HBV    Hepatitis B Virus  
hCG    Human Chorionic Gonadotropin  
HCV    Hepatitis C Virus  
HIPAA   Health Assurance Portability and Accountability Ac t 
HIV   Human Immunodeficiency Virus  
HR    Heart Rate  
HZ    Heterozygous  
IB    Investigator’s Brochure  
ICF   Informed Consent Form  
ICH International Conference for the Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
IM    Intermediate metabolizer  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
viii 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  IND   Investigational New Drug  
IRB   Institutional Review Board  
ISM   Independent Safety Monitor  
ITT   Intent -To Treat  
IVIVC    In-Vitro In -Vivo correlation  
LOQ    Limit of Quantification  
MedDRA   Medical Dictionary for Regulatory Activities  
MM   Medical Monitor  
MOP    Manual of Procedures  
M1    Metabolite 1  
N    Number (typically refers to subjects)  
NDA    New Drug Application  
NE    Norepinephrine  
NET    Norepinephrine Transporter  
NIDA    National Institute On Drug Abuse  
NIH   National Institutes of Health  
O-DMT   O-Desmethyltramadol  
OHRP    Office for Human Research Protection  
OHSR    Office for Human Subjects Research  
PACU    Post-Anesthetic Care Unit 
PE    Physical  Exam  
PHI   Protected Health Information  
PI    Principal Investigator  
PID#    Participant Identification Number  
PK    Pharmacokinetic  
PM    Poor metabolizers  
QA    Quality Assurance  
QC    Quality Control  
RR    Respiratory Rate  
SAE    Serious Adverse Event  
SID#    Screening Identification Number  
SR    Slow release  
SMC    Safety Monitoring Committee  
SOP   Standard Operating Procedure  
SRSDE   Subject -Rated Strength of Drug Effect  
SSP   Study Specific Procedure  
TDAA    Take Drug Again Assessment  
TEA    Treatment Enjoyment Assessment  
VAS    Visual Analogue Scale  
UM   Ultra -rapid metabolizer  
WBC    White Blood Cell  
WHO    World Health Organization  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
ix 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  Protocol Summary  (Synopsis)  
 
Protocol Number: OMNI -PAIN-103 
 
Clinical Trial Phase: Phase 1  
 
Sponsor: Syntrix Biosystems, Inc.  
 
IND Sponsor: Syntrix Biosystems, Inc.  
 
Objectives:  
 
 The purpose of the study is to investigate  in healthy human subject s desmetramadol  dose-
proportionality and food effect ( desmetramadol  is the M1 metabolite of tramadol) .  Dose proportionality 
will be assessed for 10, 20 and 30 mg single oral doses , and food effect will be assessed  for the  30 mg 
single oral dose.    
 
  Primary Objective s: 
 
To determine the dose proportionality of desmetramado l following oral single -dose administration  
of 10, 20 and 30 mg  in fasted healthy subject s. 
 
To determine the food effect on 30 mg desmetramadol  in healthy subjects following oral single -
dose administration.  
 
To determine the safety and tolerability of desmetramadol  following oral single -dose 
administration in fasted and fed healthy subject s. 
 
  Secondary Objectives : 
 
Determine PK parameters for  each M5 enantiomer in blood following oral single -dose 
administration of 10, 20 and 30 mg desmetramadol in fasted healthy subjects and of 30 mg 
desmetramadol administered with food.  
 
Quantify total M1 and M5 excreted (unconjugated and de -conjungated) in the urine after the 30 
mg fasted dosings  and compute clearance of each and in relation to 24  hr creatinine clearance . 
 
Study Population:  
 
Potential study subject s are screened and consented.   Subjects will be men and women aged 19 to 55 
years in general good health.  
 
 
Design:  
 
 An open -label , randomized, balanced, single -dose, four -treatment, four -period, four -sequence (using a 
Williams’ square design) cross -over study with each dose separated by >3 days: 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
x 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   Period  
Sequence  I II III IV 
1 30 mg, food  30 mg, fasted  10 mg, fasted  20 mg, fasted  
2 10 mg, fasted  30 mg, food  20 mg, fasted  30 mg, fasted  
3 20 mg, fasted  10 mg, fasted  30 mg, fasted  30 mg, food  
4 30 mg, fasted  20 mg, fasted  30 mg, food  10 mg, fasted  
 
 To account for potential dropouts, u p to 32 eligible subject s will be  randomized  to obtain a target 
sample of 24 subjects with PK responses at each of the four treatment periods  (based on our completed 
phase 1 study in 43 subjects, dropouts are unlikely  (~5%) ; see Section 1.2.2 ).  Before each oral dose , 
subject s will be fasted overnig ht for at least 10 hours .  Treatment sequences will include the following 
four unblinded single -dose oral treatments: 1) desmetramadol  1 x 10 mg tablet; 2) desmetramadol  2 x 10 
mg tablets; 3) desmetramadol  3 x 10 mg tablets; and 4) desmetramadol  3 x 10 mg tablets following a 
high-fat, high -calorie breakfast served approximately 30 minutes before dosing and entirely consumed 
within 20 minutes.  All subjects will fast for an additional four hours after desmetramadol  administration.  
The fed treatment should b e administered the desmetramadol  dose approximately  30 minutes after the 
start of the meal.  Desmetramadol  will be administered with approximately 240 ml of water.  No water is 
allowed one hour before and one hour after each desmetramadol  administration.  
 
 This will be an in patient study.  Subject s will be admitted to the clinical pharmacology unit  on Study 
Day -1, and administered a single oral dos e treatment on Study Day 1, Study Day 4, Study Day 7 and 
Study Day 10.  After completing study procedures on Day 11 the subject  will be discharged from the 
facility.    
 
 Blood specimens for plasma preparation and PK analysis will be collected at the follo wing times: pre -
dose (0 h), and post -dose 0.5, 1.0, 1.5, 2.0, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, and 3 2 h. 
 
 Urine will be collected as described in the Appendix A Auxiliary  to determine the clearance of M1, 
M5 and creatinine  and determine the fraction of t he desmetramadol dose excreted as M1 and M5 .   
  
 Other salient aspects of the approach to evaluating the investigational agent are enumerated below:  
 
Sample Size and Randomization:  
 
 Up to 32  subjects will be randomized to obtain a target sample of 24 sub jects with PK responses at 
each of the four treatment periods.  Desmetramadol  and tramadol are closely related chemicals and are 
therefore expected to have a similar intra -patient coefficient of variation and food -effect.  Published 
studies indicate a ~15%  intra-subject coefficient of variation for immediate release tramadol (Najib 2009, 
ESP_Pharma_Limited 2010, Dhanure 2013) , and the Ultram label indicates that “ oral administration of 
Ultram with food does not significantly affect its rate or extent of absorption, therefore, Ultram can be 
administered without regard to food.”  
 
 Dose -proportionality will be established according to the power -model Y i = α·D iβ, where  Y is the 
pharmacokinetic response (e.g., AUC, C max), α is the coefficient, β the exponent, D the dose, and i the 
fasted dose levels to be explored (i.e.,  i = 1, 2 and 3 correspond to the 10, 20 and 30 mg doses, 
respectively).  The power -model is lineariz ed by natural log transforming the equation to ln (Yi) = α + 
β·ln(Di). Strict dose linearity yields a  slope β  equal to 1.   
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
xi 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   
 Using a conservative estimate of 20% for the intra -subject coefficient of variation (CV) of 
desmetramadol , and a 5% level of signif icance, a sample size of 24 subjects is considered sufficient to 
provide 89.6% power (essentially 90% power) to establish dose -proportionality and absent food effect, 
assuming no multiplicity and a fed/fasting ratio of 0.95 and a 5% deviation  from 1 for  the slope β in dose  
proportionality .  Based on a study drop -out rate of ~30% in the Ultram label, up to 8 subjects (alternates) 
might be added to maintain a sample of 24 subjects with blood draws at each treatment period  (based on 
our completed phase 1 study  in 43 subjects, dropouts are unlikely to exceed 5%; see Section 1.2.2 ). 
 
 Randomization  of subjects will be balanced across the four treatment sequences in the 4x4 Williams’ 
design.  
 
Study Duration:  
 
 Enrollment is estimated to take approximately  30 days .  Subject s will be on study for 11 Days.  It will 
take approximately 6 weeks to complete the study after enrollment of the first subject . 
 
Study Agent:  
 
 Test desmetramadol  tablets:  10 mg slow release tablet.  
 
Endpoints:  
 
 The endpoints are p harmacokinetic ( PK) responses  for all measure d blood analytes (i.e., each 
enantiomer of M1 and M5) : T1/2, Tmax, Cmax, AUC 0-t, AUC 0-inf, and if present, T lag).  The PK responses 
relevant to dose -proportionality and food effect are  M1 AUC 0-inf (AUC 0-t when appropriate) and C max. 
 
 The urine endpoints  are CL M1, CL M5, CL CR, and the mass of M1 and M5 excreted.  Exploratory urine 
endpoints include calculating the rate constants for total elimination (k el), renal elimination (k e), and 
fraction excreted (f e) by plotting the rate of excretion ( ΔU/Δt) vs. the midpoint time of each interval.   
 
 Safety: Adverse events.  
 
Monitoring:  
 
 Syntrix Biosystems and its representatives.  
 
Clinical Site:  
 
 Celerion  
 
Bioanalytical Laboratory:  
 
 Celerion  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
xii 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  Schematic of Study Design  
Prior to   
Randomization  
 
 
 
 
 
 
 
 
 
 
Day 1- 
Day 3 
(Period I ) 
 
 
 
Day 4- 
Day 6 
(Period II ) 
 
 
 
Day 7- 
Day 9 
(Period III ) 
 
 
 
 
Day 10 - 
Day 11 
(Period IV ) 
 Obtain informed consent. Screen subjects by entry criteria.  
Admit subjects to CPU.  
On study day 1 randomize subjects to the four treatment sequences and a dminister a single 
dose of study d rug (period 1 of treatment) .  Before and after the dose PK blood and urine 
(urine only for 30 mg fasted subjects) specimens are collected.  The next dose of study drug 
is on study day 4.   
On study day 4 a dminister single dose of study d rug (period 2 of treatment) .  Before and after the dose 
PK blood and urine (urine only for 30 mg fasted subjects) specimens are collected. The next dose of 
study drug is on study day 7.  
 
On study day 7  administer single dose of study d rug (period 3 of treatment) .  Before and after the dose 
PK blood and urine (urine only for 30 mg fasted subjects) specimens are collected.  The next dose of 
study drug is on study day 10  
 
On study day 10 a dminister single dose of study d rug (period 4 of treatment) .  Before and after the dose 
PK blood and urine (urine only for 30 mg fasted subjects) specimens are collected.  Subjects are 
discharged from clinical pharmacology unit and study o n Study Day 11.   
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
1 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  1 BACKGROUND AND SCIENTIFIC RATIONALE  
 
1.1 Background Information  
 
1.1.1 Tramadol  and desmetramadol : Background and Pharmacology  
 
 Tramadol is a synthetic atypic al, centrally -acting opioid analgesic approved in the U.S. and elsewhere 
for treating moderate to severe pain with efficacy and potency between weak opioids and potent opioids 
such as morphine (Grond 2004 ).  Tramadol was developed by the German pharmaceutical company 
Grünenthal GmbH in the late 1970s under the trade name Tramal.  One of the advantages of tramadol 
over traditiona l opioids is its low er risk of opioid dependence (Raffa 2008 ).  Tramadol is a widely 
prescribed generic analgesic either alone, or together with acetaminophen , with over 25 million 
prescriptions in the U.S. in 2 009 ( http://drugtopics.modernmedicine.com ). 
 
 Tramadol is a racemate consisting of 1R, 2R -tramadol [(+) -tramadol], and 1S, 2S -tramadol [(−) -
tramadol].  After oral administration of the racemate, both the (−) and (+) forms of both tramadol and the 
O-desmethyltramadol  metabolite (O -DMT or M1 ) are detected in the circulation ( FIG. 1A ).  
desmetramadol , the test study agent, is racemic O -desmethyltramadol, and thus provides ( -) and (+) O-
DMT  without requiring metabolism.   
 
(A)          
 
 
 
 
 
 
 
(B) 
 
 Ki (μM)  
Compound  opioid receptor affinity   uptake inhibition  
 μ δ κ  norepinephrine  serotonin  
morphine  0.00034  0.092  0.57  inactive  inactive  
(+)-tramadol  1.3 62.4 54.0  2.51 0.53 
(-)-tramadol  24.8 213 53.5  0.43 2.35 
(+)-O-DMT  0.0034  - -  11-14.4 2.98 
(-)-O-DMT  0.240  - -  0.38-0.86 17.7 
FIG. 1 .  Structures  of (A) tramadol and the  active metabolite O-DMT ; and (B) relative inhibition of opioid receptors and 
monoamine transporters.   Determined and estimated from (Grond 2004 , Raffa 2012 ).  Highlighted values reflect dominant 
target of compound based on affinity.  [7]. 
 
 Each enantiomer of tramadol and O-DMT  has a different dominant receptor or transporter target 
(FIG. 1B ).  Th ese targets include  (+)-O-DMT  enantiomer binding to  the μ-opioid receptor, and  (-)-
tramadol  and ( -)-O-DMT  enantiomers binding to norepinephrine transporter  (NET) (Kayser 1991 , Kayser 
1992 , Raffa 1992 , Driessen 1993 , Desmeules 1996 ).  The ( -)-enantiomers of tramadol and O-DMT  have 
substantially equivalent in vi tro potency with respect to binding the NET and inhibiting NE reuptake.  
 
N
HO
OCH3
TramadolN
HO
OH
O-desmethyltramadol (M1)
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
2 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   Two synergistic mechanisms are believed involved in tramadol and O-DMT  mediated analgesia.  
First, supraspinal μ-opioid receptor agonism by (+) -O-DMT  increases serotonin and NE in the dorsal horn 
of the spinal cord via descending pathways originating from the locus c oeruleus  and possibly other areas  
(Ide 2006 ).  Second, the released spinal NE is potentiated by the ( -)-tramadol and ( -)-O-DMT  enantiomers 
blockade at the NET.  The accumulated NE exert s antinociceptive action by reducing neurotransmitter 
release from primary afferent  nerve s.  
 
 In addition to the pharmacology of (+) -O-DMT , (-)-O-DMT , and ( -)-tramadol , the (+) -enantiomer of 
tramadol directly inhibits serotonin reuptake (FIG. 1B ) (Driessen 1992 , Bamigbade 1997 ).  Studies 
conducted in the µ-opioid receptor knockout mouse demonstrated that serotonin reuptake inhibition is not 
involved in trama dol an algesia (Ide 2006 ).  Furthermore , the tramadol (+)-enantiomer inhibition of 
serotonin reuptake may trigger  the serotonin syndrome, a rare potentially fatal known adverse reaction of 
tramadol .  The serotonin syndrome is observed more frequently when tramadol is taken with other 
serotonin reuptake  inhibitors , e.g., antidepress ants (Sansone 2009 ).  Thus, compared to tramadol, O-DMT  
has equivalent analgesia, but substantial ly less seroton in reuptake inhibition than tramadol ( FIG. 1B ) (Ide 
2006 , Yanarates 2010 ).  Therefore O-DMT  (desmetramadol ), compared to tramadol , should  offer  equal 
analgesia and, through  its decreased propensity to induce the serotonin syndrome , both improved safety 
and improved drug-drug compatibility.   
 
 Tramadol has 75% oral bioavailability, with peak serum concen trations reached within 2 hours (Grond 
2004 ).  Tramadol e limination kinetics are two -compartmental ; after a single 100 mg oral dose  of 
tramadol, tramadol half-life is 5.1 hours and 9 hours for O-DMT .  The FDA approved  dose of tramadol is 
50-100 mg every 4 to 6 hours, with a maximum dose of 400 mg/day; the duration of the analgesic effect 
after a single oral dose of tramadol 100 mg is about 6 hours.  
 
 Tramadol is metabolized as follows, and desmetramadol is not expected to yield M2, but only M5:  
 
 
  

Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
3 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  1.1.2 Unmet Need: Absent Tramadol Efficacy in Patien ts with Low C YP2D6 
Activity  
 
 Most individuals rapidly and extensively metabolize  tramadol  in the liver  principally by the  
cytochrome P -450 (CYP) isoenzymes CYP 2D6 and CYP 2B6 (O -desmethylation) , and CYP 3A4 (N -
desmethylation).  Importantly, following tramadol administration O-DMT  generation is dependent on 
CYP 2D6.  Approximately 7 -10% of Caucasians have two inactive CYP2D6 alleles, and  no or severely 
reduced  CYP2D6  activity.  These indivi duals are poor metabolizers  (PMs) of tramadol , and following 
tramadol administration their M1 serum concentration is below the therapeutic range (50 -100 ng/mL) 
after a 10 0 mg oral (Kirchheiner 2008 ) or iv dose (Enggaard 2006 ), being almost undetectable or below 
the limit of detection compared to extensive metabolizers (EMs) with two normal allele s, and confirming 
the dominant role of CY P2D6 in O -demethylation of tramadol in humans (FIG. 2A ). 
 
 In addition to genetic deficiency of CYP2D6, studies have shown that patients with one or two normal 
CYP2D6 may be functionally deficient as a result of concurrent use of a drug that inhibits CYP2D 6.  
These patients are said to be “phenoconverted” to poor metabolizers.  Such findings are clinically 
important to the relevance of desmetramadol , because multiple medication use is common in clinical 
practice , and increases the risk of CYP2D6 phenoconver sion and non -response to tramadol.  
Phenoconversion is unpredictable  and is not detected by genetic testing.  In one study of a university 
hospital medication database in Finland, e very fifth patient receiving tramadol was concomitan tly taking 
another drug that had  the potential to inhib it its activation to O-DMT  (Tirkkonen 2004 ).  In another large -
scale study that assessed the incidence of phenoconversion to CYP2D6 poor metabolizer status in patients 
being treated for depression in clinical practice in the U.S. (Preskorn 2013 ), the rate of phenoconversion 
was 27%.  The incidence of CYP2D6 poor metabolizer status based on phenotype was ~7 times larger 
than that expec ted based on genotype.   
 
 Consistent with O-DMT  being critical to mediating tramadol analgesia, several human studies have 
shown that tramadol efficacy is significantly decreased or lacking in PM patients.  In the first study, using 
two parallel, randomiz ed, double -blind, placebo -controlled crossover designs, the analgesic effect of 
tramadol was assessed in 27 volunteers (15 EMs and 12 PMs) using several experimental pain models 
(Pouls en 1996 ).  Sufficient differences were noted between the EMs and the PMs to indicate  that O-DMT  
is critical for the analgesic effect of tramadol on experimental pain.  
 
 In the second study, the effect of CYP2D6 polymorphism on tramadol analgesia was ass essed in 300 
Caucasian patients underg oing major abdominal surgery (Stamer 2003 ).  Patients who had one or more 
functional alleles  were classified as EMs.  Genotyping revealed that 35 patients were PMs.  Compared to 
the EMs, the PMs displayed a significantly higher incidence of non -response (P = 0.005) and frequently 
required rescue medication (P = 0.02).  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
4 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   
FIG. 2   (A) Tramadol and O-DMT  plasma concentrations over time in subjects with different CYP2D6 genotypes; PM vs. EM.  
All subjects received 100 mg dose of tramadol po .  (B) Non -responders to tramadol treatment allocated to genotypes. Grey 
columns: % of patients needing rescue medicat ion in the post -anesthetic care unit (PACU); black columns: % of non -
responders after the 48 -h study period. *P<0.001 for the PM group compared with the HZ/IM, EM, and UM groups.   
 
 In the th ird study, the effect of CYP 2D6 po lymorphism (specifically CYP 2D6*10, a SNP that results 
in a Pro34 to Ser substitution and reduced CYP 2D6 activity) on tramadol -induced analgesia was assessed 
in 63 Chinese patients who underwent ga strectomy for gastric cancer (Wang 2006 ).  The patients were 
classified as EMs (N = 17) , or heterozygous (N = 26) or homozygous (n = 20) for CYP2D6*10.  
Compared to the other groups, the homozygous group required more tramadol (P<0.05).  
 
 Finally, a fourth study of patients (N=187) undergoing major abdominal surgery reported a 4 -fold 
greater non -response rate to tramadol in PM s (Stamer 2007 ); (FIG. 2B ).   
 
 In summary, the analgesic effect of tramadol is decreased or absent in patients with low CYP2D6 
enzymatic activity (PMs) because their serum O-DMT  concentration is considerably lower .   
 
1.1.3 Significant Negative Impact on Patient Care and Safety  
 
 Tramadol is widely prescribed , with over 25 million prescriptions in the U.S. in 2009 
(http://drugtopics.modernmedicine.com).  As such, 10 -30% drug resistance in a target patient population 
due to CYP2D6 PM phenotype results in significant negative impact on patient care.  Based on an 
estimated 3:1 prescription -to-patient ratio, these data suggest that upwards of 1-2 million patients 
annually may receive inadequate analgesia from tramadol therapy.  Further more , the need to switch non -
responders to traditional opioids increases th eir ris k of opioid dependence.  
 
 Thus , there exists a need  to develop an “improved tramadol”  (desmetramadol  (O-DMT )) that would 
be effective in all patients irrespective of their metabolic status , and safer .  desmetramadol  could serve all 
patients being treated w ith tramadol , as well as a significant portion of patients who are being treated with  
conventional opioid s that are plagued with similar issues of meta bolic variability . 
 
(A) 
Plasma Tramadol  
 Plasma M1  
Time (hours)  
Plasma Tramadol  
Time (hours)  
(B) 
(A) 
Plasma M1  
 Plasma Tramadol  
Time (hours)  
(B) 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
5 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  1.2 Description of the Study Agent  
 
1.2.1 Pilot Study of Desmetramadol  in a Human Subject  
 
1.2.1.1  Single Dose Pharmacokinetics  
 
 Single -dose pharmacokinetics of tramadol and desmetramadol  are shown in FIG. 3.  In the Hagelberg 
study, 12 healthy subjects were randomized in three segments to ingest 50 mg of tramadol after 4 days of 
pretreatment with either placebo, ticlopidine (250 mg twice daily) or ticlopidine plus itraconazole (200 
mg once daily).  Data for the M1 exposure in the placebo treated subjects is shown.  M1 exposure for a 
single 100 mg tramadol dose is from the Ultram la bel and the Grond review.  The pharmacokinetic 
parameters for M1 exposure from 20 mg desmetramadol  approximates those for 50 mg tramadol.  
 
Drug   tramadol  tramadol  desmetramadol  (M1)  
Study   (Hagelberg 2013 ) Ultram label, (Grond 2004 ) (SYN -PAIN -115 2011 ) 
n  12 12 1 
population   healthy adult  healthy adult  healthy adult  
Route   oral oral oral 
Dose (mg)   50 100 20 
Fasting   Fasted then meal at 4 and 8 
hours  “food does not significantly 
affect its rate”  Fasted 30 min before and after 
dosing  
M1 Exposure      
 AUC (ng-h)/mL   367 722 229 
 Cmax (ng/mL)   34 55.0 28.8 
 Tmax  2.7 3.0 3.6 
 Half-life (hr)   6.6 6.7 6.0 
FIG. 3.  Single -dose PK parameters for M1 exposure in man from 50 and 100 mg tramadol and 20 mg desmetramadol . 
 
  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
6 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  1.2.1.2  Steady -State Pharmacokinetics  
 
 The approved oral dosage of tramadol is 50 -100 mg q 6 hours, and the mean steady -state level of M1 
produced by this approved dosage is ~55 -110 ng/mL (see Ultram label).  This is the same steady -state M1 
level produced by 20 -30 mg oral desmetramadol  q 6 hou rs (i.e., 2-3 10 mg desmetramadol  tablets q 6 
hours) (FIG. 4).  Importantly however, desmetramadol  achieves therapeutic M1 levels without requiring 
metabolism by CYP2D6, thus obviating the shortcomings of tramadol related to CYP2D6.  
 
(A) (B) 
  
FIG. 4.  Steady -state data for tramadol and desmetramadol  in a healthy male human subject.  Black traces in ( A) and ( B) are 
dose 9 (48 -54 hours) and 10 (54 -60 hours) of tramadol q 6 hours: 25 mg (squares), 50 mg (circles), 75 mg (triangles), 100 mg 
(diamonds).  Purp le traces represent dose 9 and 10 of desmetramadol  (10 mg tablet) q 6 hours: 20 mg ( A) and 30 mg ( B). 
 
1.2.2 Phase 1 PK and PD Study in Normal Healthy Volunteers  
 
 In October 2014 the Sponsor com pleted a phase 1 trial entitled  “A Phase 1 Randomized, Double -
Blind, Placebo -Controlled, Double  Cross -Over Study Investigating t he Safety, Oral Steady -State 
Pharmacokinetics, and Clinical Activity of 20 Mg desmetramadol  and 50 Mg Tramadol i n Normal Human 
Subjects ”.  Briefly, 42 males in n ormal health, 21 to 55 years of age, were inpatients for 3 days at a 
clinical pharmacology  unit and randomized to three parallel arms (N=14 each) to ingest a total of 9 
blinded doses of desmetramadol  (two 10 mg tablets), tramadol (one 50 mg tablet), or pla cebo in a first 
treatment segment (one dose every 6 hours).  Immediately before the 9th dose, and at times (1.0, 1.5, 2.0, 
2.5 and 4.0 hours) after the 9th dose blood samples were collected to quantify plasma M1 and tramadol 
enantiomers to identify Css min and Css max.  Pain tolerance was assessed in the cold pressor test at three 
sequential time points (1.0, 2.0, and 3.0 hours) after the 9th dose and averaged to provide a single value for 
subsequent analyses.  The cold pressor test involved non -dominant hand  immersion in ice -cold water (2 
°C ± 0.5°C) for up to 3 minutes, an established experimental pain measure used in previous studies of 
tramadol (Poulsen 1996 , Hagelberg 2013 ).  Measurements included (a) time to first pain perception, (b) 
pain intensity at first pain perception, (c) pain  at 30 seconds, (d) pain at 60 seconds, (e) total time 
immersed not to exceed 3 minutes.  Subjects were discharged from the clinical pharmacology unit  after 
the last blood draw and washed out for 7 days (i.e. , after the first and second treatment segments)  before 
being readmitted. The endpoint analyses included the steady -state parameters Css min and Css max, pain 
tolerance, and safety.  
 
020406080100120
48 50 52 54 56 58 60Plasma M1 (ng/mL)
Time (hours)
020406080100120
48 50 52 54 56 58 60Plasma M1 (ng/mL)
Time (hours)
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
7 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   The PK equivalence of desmetramadol  to tramadol was evaluated using the log -transformed Css min 
and Css max of M1 (note only  two genetic CYP2D6 PMs were in th e population).  Formal bioequivalence 
is claimed for a Css parameter when the 90% confidence interval of its desmetramadol -to-tramadol ratio 
falls within 0.8 and 1.25 (Rani 2007 ).  Pain tolerance for desmetramadol , tramadol and placebo  were 
compared using a mixed effects linear model with treatment, period, and sequence as fixed effects and 
subject as a random effect nested within sequence. Period was added as a fixed effect to find any 
significant first -order crossover effects. If sign ificant treatment effects were present, least squares means 
were compared between desmetramadol  and placebo treating placebo as a control using the Dunnett’s 
procedure.  
 
 Steady -state dosing of 20 mg desmetramadol  was formally bioequivalent to 50 mg tramad ol with 
respect to plasma (+) -O-desmethyltramadol ( FIG. 5A).  desmetramadol  was nearly formally 
bioequivalent with respect to ( -)-O-desmethyltramadol: Css min (21+5 v. 30 +6 ng/mL) and Css max (30+9 v. 
42+9 ng/mL). This Phase 1b trial confirmed the earlier pi lot data, and showed desmetramadol  indeed 
successfully “flattened” the steady -state blood levels of M1 between doses in a manner equivalent to that 
obtained with tramadol ( FIG. 5B).  Twenty  mg desmetramadol  is therefore a therapeutic substitute for 50 
mg tramadol with respect to the steady -state delivery of M1, a finding that informed the desmetramadol  
dose selected for this phase 1 trial to examine the effect phenoconversion of CYP2D6 on desmetramadol  
and tramadol analgesia in normal subjects . 
 
 Evaluation  of total time immersed in the cold pressor test revealed a significant difference between 
desmetramadol  vs. placebo ( P = 0.0060) and tramadol vs. placebo ( P = 0.0076) ( FIG. 5C).  A significant 
difference was also found between desmetramadol  and placebo for time to first pain perception ( P = 
0.0057), and pain at 30 seconds ( P = 0.0019).  Data was lacking for pain at 60 seconds due to hand 
withdrawal  before 60 seconds .  The adver se events after desmetramadol  and tramadol were similar ( FIG. 
5D). 
 
  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
8 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  (A) (C)  
 
Treatment  Css min Css max Css mean 
 ng/mL  ng/mL  ng/mL  
20 mg 
desmetramadol  
(test)  26 + 6 36 + 10 31 + 7 
50 mg Ultram IR  
(reference)  28 + 7 37 + 10 33 + 8 
90% CI of ratio  0.85-1.08*  0.88-1.13*  - 
*90% CI within 0.80 -1.25; formally bioequivalent.  Mean +SD. 
 
(B) 
 
 (D) 
 
Preferred Term  desmetramad
ol 
(n=43)  tramadol  
(n=41)  placebo  
(n=41)  
Dizziness   5 ( 12%)   5 ( 12%)   1 (  2%)  
Headache   3 (  7%)   6 ( 15%)   0 (  0%)  
Nausea   8 ( 19%)   5 ( 12%)   3 (  7%)  
Pruritus   0 (  0%)   1 (  2%)   0 (  0%)  
Pruritus generalized   3 (  7%)   3 (  7%)   0 (  0%)  
Somnolence   3 (  7%)   2 (  5%)   0 (  0%)  
Urinary hesitation   1 (  2%)   2 (  5%)   0 (  0%)  
Vomiting   1 (  2%)   1 (  2%)   0 (  0%)  
 
 
 
FIG. 5.  Summary of results from Phase 1b trial.  ( A) tabular and ( B) graphical summary (mean +SD) of steady -state plasma 
+M1 due to 20 mg desmetramadol  q6 hr and 50 mg tramadol q6 hr.  ( C) Graphical summary total immersion time in cold 
pressor test as a function of treatment with placebo, tramadol and desmetramadol  (horizontal bar is median). The mixed effects 
linear model was applied to the data. The Type III tests of fixed effects showed  a significant treatment effect ( P = 0.0036) and 
no significant sequence or period effects.  Least square means for each treatment showed that desmetramadol  had the highest 
mean (62.8) with placebo having the lowest mean (50.0).  After observing a signific ant treatment effect, Dunnett’s procedure 
was run to find which study treatments were significantly different than the control (placebo).  Dunnett’s procedure indicate d a 
significant difference between both desmetramadol  vs. placebo ( P = 0.0060) and tramad ol vs. placebo ( P = 0.0076). ( D) 
Tabular summary of adverse events.   
 
1.3 Rationale  
 
1.3.1 Overall Study Design  
 
 For this study , Syntrix Biosystems, through its CMO, has manufactured desmetramadol  10 mg SR 
tablets (10 mg SR O-DMT ) to be the test drug.  This study  will investigate in male and female subjects  
single -dose oral PK  responses  of desmetramadol  (test drug ) following administration: in a fasted state of 
10 mg (1x10 mg tablet ); 20 mg (2 x10 mg tablets) ; and 30 mg (3 x10 mg ta blets) ; and in a fed state: 30 mg 
(3x10 mg tablets) .   
 
 This protocol is designed to perform a  randomized, open -label , four sequence, four period,  cross -over 
study to analyze the fasted -state oral dose proportionality of desmetramadol , and the effect of f ood on  
desmetramadol . 
Total time (sec)
Placebo Tramadol Omnitram020406080100100150200
020406080100120
0 1 2 3 4Plasma (+) -O-Desmethyltramadol 
(ng/mL)
Time After 9th Dose (hours)50 mg Tramadol
20 mg Omnitram
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
9 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   
1.3.2 Dosage  
 
 The rationale for the efficacy and safety of the 10 mg, 20 mg, and 30 mg single dose  desmetramadol  
SR is based on 20 mg desmetramadol  providing a similar M1 C max as does the FDA -approved single dose 
of 50 mg tramadol, and 20 mg desmetramadol  providing the same steady -state M1 exposure as does the 
FDA -approved dosing of 50 mg  tramadol every  6 hours .  The extensive public database on the safety and 
adverse events as sociated with the use of tramadol  at the approved dosing of 50 -100 mg q 6 hours  defines  
the safety profile of 10 mg, 20 mg, and 30 mg of  desmetramadol  SR. 
 
1.3.2.1   Nonclinical Toxicology Data  
 
 See the Investigator’s Brochure.  
 
1.3.2.2   Clinical Data    
 
 See the Investi gator’s Brochure.  
 
1.3.3 Study Pop ulation  
 
 For this phase 1 study , the study population is male and female volunteers in normal health 19 to 55 
years of age .   
 
1.3.4 Study Endpoints  
 
 The endpoints are pharmacokinetic (PK) responses  for all measured blood analytes (i.e., each 
enantiomer of M1 and M5) : T1/2, Tmax, Cmax, AUC 0-t, AUC 0-inf, and if present, T lag).  The PK responses 
relevant to dose -proportionality and food effect are  M1 AUC 0-inf (AUC 0-t when appropriate) and C max. 
 
 The u rine endpoints are CL M1, CL M5, CL CR, and the mass of M1 and M5 excreted.  Exploratory urine 
endpoints include calculating the rate constants for total elimination (k el), renal elimination (k e), and 
fraction excreted (f e) by plotting the rate of excretion ( ΔU/Δt) vs. the midpoint time of each interval . 
 
 Safety endpoints  are adverse events.  
 
1.4 Potential Risks and Benefits  
 
 Significant risks or benefits are not expected .  Formally, however, p otential physical risks include 
side-effects commonly known to be associated with tramadol.  The side -effects from the test drug 
desmetramadol  are not expected to be qualitatively or quantitatively worse than the side -effects arising 
from tramadol .  Additi onal risks associated with any pharmacokinetic study are also possible including 
minor bruising and hematoma at the si te of v ein puncture.   
 
 The eventual availability of desmetramadol  for pain will be beneficial as an alternative to tramadol  as 
it will re sult in fewer analgesic non-responders .   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
10 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  2 STUDY OBJECTIVES  
 
 The purpose of the study is to investigate in healthy human subject s desmetramadol  dose-
proportionality and food effect ( desmetramadol  is the M1 metabolite of tramadol).  Dose proportionality 
will be assessed for 10, 20 , and 30 mg single oral doses , and food effect will be assessed  for the 30 mg 
single oral dose .  The primary objectives are to:  
 
• Determine the dose proportionality of desmetr amadol  following oral single -dose administration of 10, 
20, and 30 mg in fasted healthy subjects .  
 
• Determine the food effect on 30 mg desmetramadol  in healthy subjects following oral single -dose 
administration . 
 
• Determine the safety and tolerability of desmetramadol  following oral single -dose administration in 
fasted and fed healthy subjects . 
 
• Determine PK parameters for each  M5 enantiomer in blood following oral single -dose administration 
of 10, 20 and 30 mg desmetramadol in fasted healthy subjects and of  30 mg desmetramadol 
administered with food.  
 
• Quantify total M1 and M5 excreted (unconjugated and de -conjungated) in the urine after the 30 mg 
fasted dosings  and compute clearance of each and in relation to 24 hr creatinine clearance . 
 
3 STUDY DESIGN  
 
3.1 Description of the Study Design  
 
 An open -label, randomized, balanced, oral single -dose, four-treatment, four -period, four-sequence 
(using a Williams’ square design) cross -over study as follows:    
 
 Period  
Sequence  I II III IV 
1 30 mg, food  30 mg, fasted  10 mg, fasted  20 mg, fasted  
2 10 mg, fasted  30 mg, food  20 mg, fasted  30 mg, fasted  
3 20 mg, fasted  10 mg, fasted  30 mg, fasted  30 mg, food  
4 30 mg, fasted  20 mg, fasted  30 mg, food  10 mg, fasted  
 
 To account for potential dropouts, up to 32  male and female subject s, 19 to 55  years of age, could be 
randomized to obtain a target sample of 24 subjects with PK responses at each of the four treatment 
periods  (based on our completed phase 1 study in 43 subjects, dropouts are unlikely; see Section 1.2.2 ).  
Before each oral dose , subject s will be fasted overnight  for at least 10 hours . Treatment sequences will 
include the following 4 unblinded single -dose oral treatments: 1) desmetramadol  1 x 10 mg tablet; 2) 
desmetramadol  2 x 10 mg tablets; 3) desme tramadol  3 x 10 mg tablets; and 4) desmetramadol  3 x 10 mg 
tablets following a high -fat, high -calorie breakfast served approximately 30 minutes before dosing and 
that is to be entirely consumed within 30 minutes.  Each dose will be separated by 3 days.  All subjects 
will fast for an additional four hours after desmetramadol  administration.  The fed treatment should be 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
11 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  administered and the desmetramadol  dose administered approximately 30 minutes after the start of the 
meal.  Desmetramadol  will be administered with approximately 240 ml of water.  Only water is allowed 
one hour before and one hour after each desmetramadol  administration .  
 
 This will be an in -patient study.  Subject s will be admitted to the clinical pharmacology unit  on Study 
Day -1, and administered a single oral dose treatment on Study Day 1, Study Day 4, Study Day 7 and 
Study Day 10.  After completing study procedures on D ay 11 the subject  will be discharged from the 
facility.    
 
 Blood specimens for plasma preparation and PK analysis will be collected at the following times: pre -
dose (0 h), and post -dose 0.5, 1.0, 1.5, 2.0, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, and 3 2 h. 
 
 Urine will be collected as described in the Appendix A Auxiliary  to determine the clearance of M1, 
M5 and creatinine and determine the fraction of the desmetramadol dose excreted as M1 and M5 . 
 
 Safety will be assessed while subjects are inpatients for each of the four treatment  segment s.   
 
 After the study drug dosing and evaluations are completed the subjects wi ll be discharged from the 
clinical pharmacology unit .  
 
 Blood will be obtained for: 1) safety assessment at screening and on Day  11; and 2) for 
desmetramadol  PK assessment on Days 1, 2, 4, 5, 7, 8, 10, and 1 1.   
 
3.2 Study Endpoints  
 
3.2.1 Primary Endpoint -Pharmacokinetic  Response s 
 
 The primary endpoints are pharmacokin etic (PK) responses  for all measure blood analytes (i.e., each 
enantiomer of M1 and M5) : T1/2, Tmax, Cmax, AUC 0-t, AUC 0-inf, and if present, T lag).  The PK responses 
relevant to dose -proportionality and food effect are  M1 AUC 0-inf (AUC 0-t when appropriate)  and C max.   
 
The urine endpoints are CL M1, CL M5, CL CR, and the mass of M1 and M5 excreted.  Exploratory urine 
endpoints include calculating the rate constants for total elimination (k el), renal elimination (k e), and 
fraction excreted (f e) by plotting the rate of excretion ( ΔU/Δt) vs. the midpoint time of each interval.  
 
The PK parameters will be determined from the desmetramadol  concentrations in the blood and urine 
samples collected before and after each study drug dose. To determine dose pro portionality , results will 
be compared between the three fasted  treatment groups (fasted desmetramadol : 10 mg, 20 mg, and 30 
mg).  To determine food effect , results will be compared between the two 30 mg dose treatment groups 
(fasted and fed) .   
 
3.2.2 Secondary  Endpoint -Safety  
 
 Any abnormal laboratory values, abnormal vital signs, reported symptoms, or abnormal physical 
examination findings determined to be clinically significant by the Investigator/designee will be 
documented as adverse events. The safety assessments will be based on all reported adverse events, and 
changes in laboratory values from baseline.  The severity and relationship t o desmetramadol  treatment 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
12 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  will be recorded for all adverse events. Adverse events will be coded for summary and analysis using 
standardized preferred terms and system organ class .   
 
3.3 Study Site  
 
 This trial will be conducted at a clinical pharmacology  unit.  Study products will be stored at the site 
under controlled conditions.  
 
4 STUDY POPULATION  
 
 The study populati on is male and female subject s in normal health to be evaluated at the clinical 
pharmacology unit .  A subject  is considered enrolled in the study o nce they have completed the informed 
consent, completed the screening  assessments , found to be eligible, and ha ve been randomized.  The goal 
is to enroll sufficient subjects so that 24 subject s complete the study  with PK specimens collected for each 
period .  The subjects will be randomized on Day 1 to one of  four sequences, with each sequence having 
four treatments  (e.g., after fasting either 10 mg, 20 mg, 30 mg desmetramadol ; or after a high fat meal , 30 
mg desmetramadol ).  The study population is defined by all randomized subjects.  
    
 Children and subjects less than 19 years of age will be excluded from this phase 1 study.  The study 
will not enroll children, pregnant women, prisoners, or other vulnerable populations.  The study is 
therefore exempt from 45 CFR 46 Subparts B, C , and D.  
 
 The study population will include all subjects who have been randomized.  The safety population will 
include all subject s who have been randomized and have received study drug.  The pharmacokinetic 
population will  be defined in the SAP . 
 
4.1 Subject  Inclusion Criteria  
 
 During  screening , subject s must meet all of the following inclusion criteria to participate in this study:  
 
1. Healthy male s and females  with vital signs  as follows at screening : systolic blood pressure  > 90 mm 
Hg and < 140 mm Hg ; diastolic blood pressure  > 40 mm Hg and  < 90 mm Hg ; pulse 40 to 99 beats 
per minute; r espiratory rate 12 to 2 4 breathes per minute . 
 
2. Age 19 to 55 years . 
 
3. Able and willing to give informed consent  
 
4. Able to comply with all study procedures . 
 
5. If female, must not be of childbearing potential or must agree to use one or more of the following 
forms of contraception from  screening , throughout the study and for 30 days following study drug 
administration: hormonal (e.g., oral, transdermal, intravagi nal, implant or injection  for 3 months ); 
double barrier (e. g., condom  or diaphragm with spermicide); intrauterine device (IUD) or system 
(IUS)  (for 3 months) ; vasectomized partner (6 months minimum); or abstinence.  
 
Screening laboratory results must be wit hin normal range , or judged by the PI to be not clinically 
significant : serum sodium, potassium, calcium, BUN, creatinine, ALT, AST, total bilirubin, alkaline 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
13 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  phosphatase, glucose (random), albumin, total protein, WBC and differential, hemoglobin, and 
platelets. In addition PT and PTT must be < 1.2 ULN.   Urinalysis demonstrating < +1 glucose, and +1 
protein.  
 
6. Electrocardiogram  (ECG)  without clinically significant abnormalities . 
 
7. If female, must have a n egative pregnancy test at screening  and when performed on Day -1 
(Appendix A ). 
 
8. Negative urine test for substances of abuse , including opiates,  per clinical pharmacology unit  
standards  at screening and  clinic  check -in. 
 
9. Negative serology tests for HIV, hepatitis B surface antigen , and hepatitis C virus antibody.  
 
10. Weight > 50 Kg and a b ody mass index (BMI)  of 18.0 to 32.0 kg/m  (inclusive) . 
 
11. Non-smoker of tobacco for a minimum of the past 3 months , and negative urine continine test . 
 
4.2 Subject  Exclusion Criteria  
 
 During  screening , subject s meeting any of the following exclusion criteria will be excluded from 
study participation:  
 
1. Oral temperature > 38°C or current illness.  
 
2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g. , head trauma, metabolic 
disorders, alcohol  or drug withdrawal) . 
 
3. History of cirrhosis or laboratory evidence of liver disease.  
 
4. Having undergone gall bladder removal.  
 
5. Use of alcohol  within 24 hours of day -1 until the end of the study;  and grapefruit , grapefruit -related 
citrus fruits (e.g., Seville or anges, pomelos ), or grapefruit juice or grapefruit -related  juice s within 7 
days of study drug administration  and until the end of the study . 
 
6. History of previous anaphylaxis, severe allergic reaction to tramad ol, codeine , or other opioid  drugs.   
 
7. Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the 
study drug as determined by the principal Investigator . If the appropriateness of a participants 
enrollment is unclear the  the Sponsor ’s Medical Monitor  can be consulted . 
 
8. Females must not be c urrently pregnant or breast feeding.  
 
9. Unlikely to comply with the study protocol.  
 
10. Known or suspected alcohol or drug abuse with in the past 6 months.  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
14 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  11. Received another investigational agent within 4 weeks of Day -1, or within five half -lives of Day -1, 
whichever is longer;  or receiving any other investigational agent during this study.  
 
12. Any concurrent disease or condition that in the opinion of the investigator impairs the subject’s ability 
to complete the trial.  Psychological, familial, sociological, geographical or medical conditions which , 
in the Investigator’s opinion , could compromise compliance with the objectives and procedures of this 
protoc ol, or obscure interpretation of the trial data.  
 
5 STUDY AGENT/INTERVENTIONS  
 
5.1 Study Drug ( Desmetramadol ) 
 
 Desmetramadol  is an analgesic in the same class as tramadol  (see FIG. 1  for chemical structures).  For 
comprehensive safety information on the study d rug please refer to the Investigator’s Brochure.  
 
5.1.1 Formulation, Packaging, and Labeling  
 
 Syntrix will provide desmetramadol  10 mg SR tablets .  For shipment to the clinical pharmacology 
unit, desmetramadol  tablets  will be packaged in bulk in bottles  labele d as follows:  
 
 
5.1.2 Study Drug Storage and Stability  
 
 Study drug will be stored at 15 -30°C.  The supplies should only be accessible to person(s) authorized 
to dispense them.  As soon as the pharmacist or clinical team member receives the study drug, the clini cal 
study supply shipping form must be completed and returned to Syntrix or its designate.  The clinical team 
member should retain a copy of this form for the Investigator’s file.  
 
5.1.3 Preparation, Administration, and Dosage of Study Drug  
 
 At the time of dosing on Day 1 the subject  will be randomized to one of four treatment  sequences .  
Subject  treatment randomization  will be performed by a pharmacist , investigator , or investigator  designee  
at the clinical pharmacology unit  using a treatment  randomization list provided by Syntrix Biosystems  or 
designee . The randomization list will: 1) assign a PID#; and 2) indicate the subject ’s treatment sequence .   
 
 The study drug will be administered orally after all protocol specified pre-dose study procedures are 
completed (see Appendix A).  Only water is allowed one hour before and one hour after each 
desmetramadol  administration. The study drug will be administered at time 0 hour  to each subject in a 

Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
15 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  sitting posture with  approximately  240 mL of water at ambient temperature by trained study personnel in 
each period. Subjects will be instructed not to chew or crush the tablet (s) but to consume it /them  as a 
whole. Compliance with dosing will be assessed by a thorough check of the oral cavity immediately after 
dosing. Subjects will remain seated for two hours after dosing in each period except when clinically 
indicated to change posture or in case of any natu ral exigency . Thereafter, the subjects will be allowed to 
engage in normal activities, including eating solid food, but while avoiding severe physical exertion .    
 
5.1.4 Study Drug Shipping and Accountability Procedures  
 
 Desmetramadol  drug bottles will be ship ped protect ed from moisture and insulated enabling  
appropriate temperature control with a temperature recording device.  The temperature recording device 
will be returned by the recipient to the shipper or designate for extraction of the shipment temperatu re 
data.  Syntrix , or its designe e, will keep a record of each shipment, along with the temperature data, for 
future reference.  
 
 All used canisters will be retained by the clinical pharmacology unit  until the study monitor performs 
a complete drug account ability audit.  Following this accounting, used canisters may be discarded 
according to clinical pharmacology unit  policy , or returned to Syntrix.  
 
5.2 Assessment of Subject  Compliance with Study Drug  
 
 Assessment of compliance with administration of study dr ug in this trial is at the level of the 
Investigator .  All study drug will be administered to subjects as inpatients at the clinical pharma cology 
unit. 
 
5.3 Concomitant Medications and Procedures  
 
 Concomitant medication  use will be queried from Study Day -1 through S tudy Day 11, and any 
reported medications  will be recorded on the concomitant medications CRF .  
 
5.4 Precautionary and Prohibited Medications and Procedures  
 
5.4.1 Prohibited Medications and Procedures   
 
• Use of alcohol within 24 hours of d ay -1 until the end of the study; and grapefruit, grapefruit -related 
citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice or grapefruit -related juices within 7 
days of study drug administration  and until the end of the study . 
 
• MAO Inhibitors  (including linezolid) , Serotonin -Reuptake Inhibitors,  Serotonin -Norepinephrine 
Reuptake Inhibitors, drugs known to  induces or inhibit drug metabolism , including CYP2D6 , and 
other drugs that may affect the serotonergic neurotransmitter systems including, b ut not limited to, 
triptans, dextromethorphan, tricyclic antidepressants, bupropion, lithium, tramadol, dietary 
supplements such as tryptophan and St. John’s Wort, and antipsychotics or other dopamine 
antagonists  are prohibited from 14 days before Study Da y -1, or 5 half -lives, whichever is longer, until 
the end of the study (Study Day 11). 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
16 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  • Prescription medications (excluding contraceptive medications  or hormone replacement therapy ) and 
nonprescription medications, including dietary supplements and herbal remedies, are prohibited from 
14 days before Study Day -1, or 5 half -lives, whichever is longer, until the end of the study (Study 
Day 11).   
 
• At any time while on study, elective surgical procedures.  
 
6 STUDY PROCEDURES and EVALUATIONS  
 
 The informat ion outlined in this Procedures and Evaluations section will be more readily followed if 
read in conjunction with the tabular listing of this informatio n in the Schedule of Procedures and  
Evaluations in Appendix A.  All assessments, unless otherwise specified, should be performed  within  
approximately  15 minutes of the indicated time . 
 
6.1 Screening (≤ 30 days  Before Day-1) and Check -In (Day -1) 
 
 Perform informed consent and ob tain signed infor med consent for m. 
 
 Assign a Screening Identification number (SID #) and record it in the Screening Enrollment Log.  
 
 Review contraception requirements with femal e subjects (section 4.1) 
 
 Perform and record medical history  including current medications and those taken within the past 
6 weeks , any signs and symptoms being experienc ed, i.e., adverse events , vital signs , collection of 
safety lab test specimens , including viral serologies, sample for serum pregnancy test (beta -HCG) 
if subject is female, urine test for substances of abuse , and E CG.  Calculate BMI.    
 
 Determine if subj ect meets eligibility criteria.   Volunteers who meet all entry criteria can be 
scheduled for check -in on  Day -1. 
 
 At check -in, assess continued eligibility with respect to the inclusion criteria (including normal 
vital signs), and exclusion criteria  (including oral temperature > 38°C  or current illness) .  Obtain 
interim medical history, perform symptom driven physical examination, a nd obtain vital signs.  
Record concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs ( section 5.4). 
 Review contraception requirements with female subjects (section 4.1) 
 
 Perform u rine test for: substances of abuse; and pregnancy (female subjects only).  
 
6.2 Randomization and Study Drug Treatment Period 1 (Day 1 Through Day 3). 
 
 Randomization : review Syntrix randomization list to obtain participant  identification numbe r 
(PID#) and treatment sequence .  Randomized subject PID# is to be used on all CRFs.  
 
 On Day 1 determine if subject to be fasted (subject’s diet limited to clear liquids  for a minimum of 
10 hours pre -dose and a minimum of 4 hours after  dosing ; and diet limited to water only one hour 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
17 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  pre-dose and one hour post -dose), or served a high -fat, high -calorie breakfast approximately to 30 
minutes before dosing that is to be consumed within 20 minutes.  
 
 On Day 1 o btain study drug , provide proper diet (record if fasted or time of high-fat, high -calorie 
meal consumption), and a dminister the oral dose  according to Section 5.1.3  and record the time of 
dosing  and the absence of tablets in the oral cavity .   
 
 Record adverse events and concomitant medica tions.  
 
 Collect PK blood and urine (urine only for 30 mg fasted subjects) specimen s and process to 
specimens  as indicated in the validated method or PK specimen preparation procedure . 
 
 Approximately 35 minutes before the dose obtain PK baseline level blood specimen , and at 0.5, 1.0, 
1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 6.0, 8.0, 12, 16, 24, and 3 2 hours after the dos e, obtain a blood specimen as 
close to the nominal time point for sample collection  as possible but in no event not out side the window  
specified in the Appendix A Auxiliary .  Collect u rine as described in the Appendix A Auxiliary .  Time 
of collection of each sample will be recorded in source documents and CRF.  The specimens will be 
stored at the method validated temperatu re (e.g., -20°C  or -80°C)  until analysis is performed.  If 
specimens require shipping for analysis, then it will be by overnight courier (split 1 and split 2  must be 
sent in separate shipments) to  the Celerion designated bioanalytical laboratory  on dry ice  with sufficient 
dry ice to keep samples at -80°C for 48 hours .   
 
6.3 Study Drug Treatment Period 2 (Day 4 through Day 6) 
 
 On Day 4 determine if subject to be fasted (subject’s diet limited to clear liquids  for a minimum of 
10 hours pre -dose and a minimum of 4 hours after dosing ; and diet limited to water only one hour 
pre-dose and one hour post -dose), or served  a high -fat, high -calor ie breakfast approximately  30 
minutes before dosing that is to be  consumed within 20 minutes.  
 
 On Day 4 obtain study drug, provide proper diet (record if fasted or times of consumption), and 
administer the oral dose according to Section 5.1.3  and record th e time of dosing  and the absence 
of tablets in the oral cavity .   
 
 Record adverse events and concomitant medications.  
 
 Collect PK blood and urine (urine only for 30 mg fasted subjects) specimens and process to frozen 
plasma specimens as described in protocol section 6.2, item # 5.  
 
 Obtain vital signs.  
 
6.4 Study Drug Treatment Period 3 (Day 7 through Day 9)  
 
 On Day 7 determine if subject to be fasted (subject’s diet limited to clear liquids for a minimum of 
10 hours pre -dose and a minimum of 4 hours after dosing ; and diet limited to water only one hour 
pre-dose and one hour post -dose), or served a high -fat, high -calorie breakfast approximately  30 
minutes before dosing and that is to be consum ed within 20 minutes.  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
18 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  
  On Day 7 obtain study drug, provide proper diet (record if fasted or times of consumption), and 
administer the oral dose according to Section 5.1.3  and record the time of dosing  and the absence 
of tablets in the oral cavity .   
 
 Reco rd adverse events and concomitant medications.  
 
 Collect PK blood and urine (urine only for 30 mg fasted subjects) specimens and process to frozen 
plasma specimens as described in protocol section 6.2, item # 5.  
 
 Obtain vital signs.  
 
6.5 Study Drug Treatment Period 4 (Day 10 through Day 11)  
 
 On Day 10 determine if subject to be fasted (subject’s diet limited to clear liqui ds for a minimum 
of 10 hours pre -dose and a minimum of 4 hours after dosing ; and diet limited to water only one 
hour pre -dose and one hour post -dose ), or served a high -fat, high -calorie breakfast approximately 
30 minutes before dosing that is to be consumed within 20 minutes.  
 
  On Day 10 obtain study drug, provide proper diet (record if fasted or times of consumption), and 
administer the oral dose according to Section 5.1.3  and record the time of dosing  and the absence 
of tablets in the oral cavity .   
 
 Record adverse events and concomitant medications.  
 
 Collect PK blood and urine (urine only for 30 mg fasted subjects) specimens and process to frozen 
plasma specimens as described in protocol section 6.2, item # 5.  
 
 Obtain vital signs.   
 
 On Day 11, with 24.0 h  PK blood collection, collect blood specimen for safety lab tests .  
 
 Before discharge from the clinical pharmacology unit , review the contraception requirements  with 
female subjects  (section 4.1).   
 
6.6 Subject Samples  
 
 PK samples will be stored frozen for analysis.  Safety lab blood collections will be processed by the 
clinical pharmacology unit laboratory, or designated laboratory.  
 
7 ADVERSE EVENTS  
 
7.1 Specification of Safety Parameters  
 
 The safety assessments will be based on clinical AEs reported by the subject or observed by the 
investigator (or appropriate designee) and laboratory abnornmalities considered to be clinically significant 
by the investigoator (or designee) .  AEs will be re corded on the AE CRF.  Clinical AE relationship to 
study drug will be determined by the investigator (or appropriate designee) and recorded on the AE CRF.  
Laboratory AE relationship to study drug will be determin ed or recorded on the AE CRFs.  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
19 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  7.2 Definition s 
 
7.2.1 Adverse Event  
 
 An AE is any untoward medical occurrence in a subject administered the study drug that does not 
necessarily have a causal relationship with this treatment.  An AE can be any unfavorable and unintended 
sign (including an abnormal laboratory  finding), symptom, or disease, whether or not related to the study 
drug.  
 
7.2.2 Serious Adverse Event  
 
 A Serious Adverse Event is defined as an AE occurring while subject is on study resulting in one of 
the following conditions:  
 
• Death,  
• Life Threatening* (defined as a subject at immediate risk of death at the time of the event),  
• Inpatient hospitalization or prolongation of existing hospitalization,  
• Congenital anomaly or birth defect,  
• A persistent or significant disability/incapacity.  
 
 *Any ot her important medical event that may not result in death, be life threatening, or require 
hospitalization, may be considered a SAE when, based upon medical judgment, the event may jeopardize 
the subject and may require medical or surgical intervention to p revent one of the outcomes listed above.  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the d evelopment of drug dependency or drug abuse.  
 
7.2.3 Unexpected Adverse Event  
 
 An adverse event is considered “unexpected” if it is not listed in the investigator brochure or is not 
listed at the specificity or severity that has been observed.  
 
7.2.4 Life-Threatening Event  
 
 An adverse event is considered “life -threatening” if, in the view of either the investigator or sponsor, 
its occurrence places the patient or subject at immediate risk of death. It does not include an adverse event 
that, had it occurred in a more s evere form, might have caused death.  
 
7.3 Assessment of Adverse Events  
 
 Assessment of clinical AE/SAE must be by the Investigator or appropriate designee, and should 
include the intensity (severity) of the event and the relationship to study drug.  
 
7.3.1 Severity Grading  
  
 Assessment of an AE/SAE severity must be made by the Investigator, whether clinical or laboratory.  
Severity of clinical and laboratory adverse events will be assessed by the study clinician using a protocol -
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
20 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  defined grading system as represented in Appendix C and Appendix D , adapted from similar toxicity 
grading tables used for healthy adult volunteers in vaccine clinical trials (CBER September 2007 ).     
 
7.3.2 Definition of Relationship of Adverse Events to Study Drug  
 
 All AEs will be recorded, and assessment of their relationship to study drug will be based on the 
clinical judgment of the study clinician according to the definitions set out below. For every AE, the study 
clinician will evaluate its relationship to the study drug administration based on the temporal relationship 
to administratio ns and the toxicity profile of any concomitant medication.   (NOTE: relationship is not a 
factor in determining whether an AE  is or is not reported ). 
 
 Relationship of AE to study drug:  
 
• Definitely r elated : The event:  
 
➢ follows a reasonable temporal sequence  from the time of administrat ion; and/or  
➢ follows a known response pattern to the administra tion; and 
➢ could not have been produced by other factors such as the subject’s clinical state, therapeutic 
intervention , or concomitant therapy; and 
➢ either occurs immediately following administration , oIr improves on stopping administration.  
 
• Probably r elated : The event:  
 
➢ follows a reasonable temporal sequence from the time of administra tion; and/or  
➢ follows a known response  pattern to the administration; and 
➢ could not have been produced by other factors such as the subject’s clinical stat us, therapeutic 
intervention , or concomitant therapy.  
 
• Possibly related : The event  could have been produced by other factors (such as a cli nical illness), but 
it either:  
 
➢ follows a reasonable temporal sequence from the time of administra tion; or  
➢ follows a known response pattern to the administration  
 
 There is some evidence to suggest a causal relationship (e.g., the event occurred within a r easonable 
time after administration of the trial medication).  However, the influence of other factors may have 
contributed to the event (e.g., the subject’s clinical condition, other concomitant events). Although an 
adverse drug event may rate only as “po ssible” soon after discovery, it can be flagged as requiring more 
information and later be upgraded to probable or certain as appropriate.  
 
• Not related : The event is clearly related to other factors such as the subject’s clinical state, or other 
concomitant therapy .  The alternative, definitive etiology must be documented.  
 
7.4 Reporting  Adverse Events  
 
 All AEs, regardless of severity or presumed relationship to study drug, will be documented on the AE 
CRF.  All SAEs, Grade 3 and Grade 4 AEs, must b e reported by the Principal Investigator (or designee) 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
21 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  directly to Syntrix  Pharmacovigilance within 24 hours by e -mail or telephone. The reporti ng sequence for 
all SAEs,  Grade 3 AEs , and Grade 4 AEs will be as follows:  
 
 The Principal Investigator (or desig nee) must report the event immediately (within 24 hours) to 
Syntrix Pharmacovigilance.  
 
 Syntrix Pharmacovigilance will then complete and forward an incident report by e -mail, 
containing all relevant information about the subject to the Syntrix Medical Moni tor (MM) within 
48 hours of receipt of the report of the event.  
 
 The MM must provide a written report by e -mail to Syntrix Pharmacovigilance within 2 working 
days of receipt of the initial incident report. This report must provide a recommendation as to 
whether the individual subject may continue to receive study drug (if more drug is scheduled).  
 
 Syntrix Pharmacovigilance will forward the MM’s written report and recommendation by e -mail 
to the Principal Investigator within 2 working days of receipt.  
 
 The Principal Investigator will meet the IRB reporting requirements.  
 
 All SAEs, Grade 3 AEs, and Grade 4 AEs judged to be probably or definitely related to study drug 
will be reported by Syntrix to the FDA within 15 days of receipt of the report of the event.  
 
7.5 Follow -up of Subjects with Adverse Events  
 
 All AEs must be followed to resolution or stabilization.  
 
8 Assessment of Risk  
 
8.1 Criteria for Interrupting the Study Based on Dos e-Limiting Toxicity  
 
8.1.1 Rules for Discontinuing Study Drug in an Individual Subject  
 
 The following are individual stopping  rules , as determined by the principal investigator,  that would 
result in a subject being withdrawn from  further study drug administration.  The expected toxicity profile 
of desmetramadol , the metabolic product of tram adol, should be very similar to the tramadol toxicity 
profile, which is well described (see IB) . 
 
1. Occurrence of a seizure.  
 
2. Signs or symptoms indicating serotonin syndrome , which may include mental status changes (e.g., 
agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, 
hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal 
symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can 
resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic 
instability with possible rapid fluctuation of vital signs, and mental status changes.  
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
22 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  3. Inability to tolerate study drug (e.g., ex cessive nausea, repeated vomiting, excessive diarrhea, 
respiratory depression , excessive agitation or anxiety ).  Respiratory depression is defined as 
respiratory rate of < 10 breathes/minute . 
 
4. Any clinical significant condition (e.g., a condition for which  continued study drug administration 
may pose additional risk), including but not limited to the following:  
 
• Pregnancy  
• Any Grade 4 systemic symptom, clinical or laboratory abnormality, or AE regardless of 
relationship to study drug.  
 
5. Any change in health status during the study period that would affect eligibility status of the subject as 
defined by all of the study entry criteria .  
 
8.1.2 Suspension of the Study  
 
 If safety concerns arise during the study, the Sponsor may suspend, amend or terminate the study. 
Furthermore, if the study is suspended, the Sponsor may resume the study once the safety con cern is 
resolved . 
 
8.1.3 Confirmatory Testing of Significant ( grade 3 and 4) Laboratory 
Abnormalities  
 
 Any laboratory abnormality , obtained  after study drug administration,  of grade 3 or higher should be 
repeated before declaring the abnormality legitimate for the purpose of following the algorithms in this 
section.   Grade 1 and grade 2 abnormalities are not subject to repeat testing.  To dec lare the initial grade 3 
or higher laboratory abnormality legitimate, confirmatory testing must (1) be completed as soon as 
possible following the initial abnormality, and (2) exhibit at least some abnormality consistent with the 
original finding (albeit p erhaps not of the same severity).  If confirmed in this fashion, the initial finding 
is declared legitimate and the finding acted upon per protocol.  If repeat testing demonstrates a laboratory 
value completely within normal range, the initial value is dec lared illegitimate for management purposes 
and treatment and reporting is continued per protocol as if the first finding was normal.  
 
8.2 Subject Withdrawal from the Study  
 
 Subjects will be free to withdraw from the study at any time  and for any reason. Any s ubject who 
withdraws from the study, regardless of reason, will not be re -enroll ed in this study. Reasons for 
withdrawal will be recorded on the appropriate CRF. The final report will include reasons for withdrawal.  
 
8.3 Replacement of a Subject  Who Withdraws from  Study Treatment  
 
 If subject s withdraw from study before study Day 11, additional subject s may be screened and 
enrolled  at the discretion of the Sponsor  (see Section 9.7 Sample Size Considerations) .  The Syntrix Study 
Director or designee will provide instructions on replacement treatment assignments.  
 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
23 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  9 STATISTICAL CONSIDERATIONS  
 
 Descriptive statistics for continuous variables will consist of the mean, median, geometric mean 
(where appropriate), standard deviation, CV, minimum, and maximum values. For categorical variables, 
the number and percentage of each category will be display ed for each treatment group. An alpha level of 
5% will be used. All statistical tests will be two -tailed unless otherwise stated.  
 
 Calculations and statistical analyses will be described in further detail as part of a statistical analysis 
plan (SAP) . 
 
9.1 Randomization  Procedures  
 
 All subjects who meet all entry criteria are eligible to be randomized and receive study drug 
treatments.  On Day 1 subjects are randomized .  The PID # is then conveyed to study staff for treatment 
assignment.   
 
 A minimum of 24 subjects will be enrolled and randomized.  The randomization list will be provided 
by Syntrix Biosystems or designee.  Randomization of subjects will be balanced across the four treatment 
sequences in the 4x4 Williams’ design .  Balanced randomization require s N be evenly divisible by four . 
The t reatment assignments will be made  using a computer -generated random list.  The randomization list 
will be provided to the pharmacist or designee responsible for study  drug diet and study drug 
disbursement.  This random ization list will match treatment assignment to PID #.  As subjects are 
assigned a PID # on Day 1, the pharmacist or designee will link that number to the treatment sequence 
assign ed. 
 
9.2 Plan for Statistical Summaries and Analyses  
 
9.2.1 General Considerations  
 
 The safety and intent -to-treat (ITT) population s are defined as all subjects who receive at least one 
dose of study drug .  The per -protocol  (PP) population   is defined as subjects who meet the 
inclusion/exclusion criteria, complete Study Day 11, receive all four d oses of study drug , and have 
provided for each study drug dose, at least 13 of the 1 5 PK blood samples.  The evaluable population are 
those subjects with calculable values for one or more of  AUC 0-inf  (AUC 0-t when appropriate) and /or Cmax. 
 
9.2.2 Disposition of Subjects  
 
 The following information will be summarized:  
 
• Number of subjects randomized . 
 
• Number (%) of subjects receiving all four  study drug doses . 
 
• Number (%) of subjects who discontinued the study and reasons for discontinuation . 
 
• Number (%) of subjects in the per -protocol population and reasons for those excluded . 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
24 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  • Number (%) of subjects with at least one protocol violation  and the protocol violation.  
 
• Additional as may be defined in the SAP . 
 
 Protoco l violations will be identified by the Syntrix Medical Monitor (or designee) for the trial.  
 
9.2.3 Demographic Characteristics  
 
 The summaries and statistical analyses of demographic characteristics will be provided for the safety 
population  as defined in the SA P. 
 
9.2.4 Safety Endpoints  
AEs will be coded using the most current version of Medical Dictionary for Regulatory Activities 
(MedDRA®) available at Celerion and summarized by treatment for the number of subjects reporting the 
treatment emergent adverse event (TEA E) and the number of TEAEs reported. A by -subject AE data 
listing including verbatim term, coded term, treatment, severity, and relationship to treatment will be 
provided.  
Safety data including ECGs, vital signs assessments, clinical laboratory results, w ill be summarized by 
treatment and point of time of collection.  
Descriptive statistics using appropriate summary statistics will be calculated for quantitative safety data as 
well as for the difference to baseline, when appropriate.  
Concomitant medication s will be listed by subject and coded using the most current version of the World 
Health Organization (WHO) drug dictionary available at Celerion. Medical history will be listed by 
subject.  
9.2.4.1  Dropouts Due to AEs  
 
 The number (%) of subjects who dropped out d ue to AEs will be summarized for each treatment 
group.  
 
9.2.4.2  Laboratory Data  
 
 Summaries of the actual value and change from baseline for all la boratory tests will be provided .  A 
tabulated summary of laboratory abnormalities by toxicity grade will also be provided.  
 
9.2.4.3  Vital Signs  
 
 Summaries by treatment group for all vital signs will be provided for each treatment . 
 
9.2.4.4  Interim Safety Analyses  
 
 There will be no interim safety analyses for this study.  
 
 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
25 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  9.2.4.5  Missing Data  
 
 Subjects with m issing data will be  included  in the analyses.   There will be no imputation of missing 
values.  
 
9.2.5 PK Analysis   
 
 The specified endpoints (PK responses) will be computed from the plasma  analyte levels  and urine  
volume and analyte  levels  (urine only for 30 mg fasted subjects) , and summari zed for each subject by 
treatment, and for each treatment cohort .    
 
9.3 Planned Interim Analysis  
 
 There will be no interim analysis for this study.  
 
9.4 Procedures for Deviations from Planned Statistical Analyses  
 
 The planned statistical analyses for this study will be described in detail in a statistical analysis plan  
(SAP) . Modifications or additions to the analyses of study data described herein will be described in the  
SAP. Any decisions to deviate from the planned analyses described in the protocol wil l be documented in 
the clinical study report  and an explanation provided . 
 
9.5 Appropriate Method and Timing for Analyzing Outcome Measures  
 
9.5.1 Methods and Timing for the Primary End -Point  
 
 Endpoints .  The endpoint s are PK responses  for all measured blood analytes (i.e., each enantiomer of 
M1 and M5) : Cmax, Tmax, T1/2, AUC 0-t, AUC 0-inf and if present , Tlag) derived from blood specimens 
obtained before and after each single dose study drug treatment .  The urine endpoints are CL M1, CL M5, 
CL CR, and the mass of M1 and M5 excreted (urine only for 30 mg fasted subjects) .  Exploratory urine 
endpoints include calculating the rate constants for total elimination (k el), renal elimination (k e), and 
fraction excreted (f e) by plotting the rate of e xcretion ( ΔU/Δt) vs. the midpoint time of each interval   They 
will be reported for the  ITT, evaluable  and PP  population s.  The PK responses relevant to dose -
proportionality and food effect are  M1 AUC 0-inf (AUC 0-t when appropriate) and C max.  Dose -
proporti onality and food -effect will be established using the evaluable population.   
 
 Methods .  Dose -proportionality will be established according to the power -model Y i = α·D iβ (Smith 
2000) , where Y is the pharmacokinetic response (e.g., AUC, C max), α is the coefficient, β the exponent, D 
the dos e, and i the fasted dose levels to be explored (i.e.,  i = 1, 2 and 3 correspond to the 10, 20 and 30 
mg doses, respectively).  The power -model is linearized by natural log transforming the equation to:  
 
 ln(Yi) = α + β·ln (Di) (Equation 1)  
 
 Strict dose li nearity yields a slope β equal to 1.  
 
 The common acceptance range of 0.8 –1.25 for dose proportionality is modified to account for the 
ratio of dose levels employed in this study as follows:  [1+ln(0.8)/ln(3), 1+ln(1.25)/ln (3)], which yields an 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
26 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  acceptance r ange  of [0.7969, 1.2031].   A mixed -effects statistical model based on Equation 1 can be used 
to account for correlation between repeated measurements in a given subject (Smith 2000) .  The random 
effects, as well as the fixed effects (α and β) and their 90% CI, can be estimated with MIXED procedure 
of SA S and other statistical packages.  
 
 If the 90% CI of β lies e ntirely within [0.7969, 1.2031], dose-proportionality  will be said to be proven  
for the PK response . 
 
 If at least one of the limits of the 90% CI of β lies outside [0.7969, 1.2031], dose proportionality  will 
be said to not be proven  for the PK response  (inconclusive: e.g., higher variabili ty and/or higher deviation 
from dose-proportionality  than expected).  
 
 If the 90% CI of β lies en tirely outside [0. 7969, 1.2031], dosing is disproportionate for the PK 
response . 
 
 Absent food effect will be established if  the 90 percent CI for the ratio of population geometric means 
between fed and fasted 30 mg desmetramadol  doses , based on log -transformed data, is con tained in the 
equivalence limits of 0.80 -1.25 for AUC 0-inf (AUC 0-t when appropriate) and C max (FDA Guidance for 
Industry.  Assessing the Effects of Food  on Drugs in INDs and NDAs -Clinical Pharmacology 
Considerations.   (Draft) CDER. February 2019). 
 
 The ab ove dose -proportionality and food effect analyses will be carried out using PK responses 
derived from the sum of (+) and ( -) O-desmethyltramadol.  Exploratory dose -proportionality and food 
effect analyses may optionally be carried out for PK responses deri ved from individual enantiomers.  
 
9.6 Study Hypotheses  
 
 Desmetramadol  is (1) dose -proportional for the desmetramadol  doses of 10 mg, 20 mg and 30 mg , and 
(2) oral administration of desmetramadol  with food does not significantly affect its rate or extent of 
absorption, and therefore, desmetramadol  can be administered without regard to food . 
 
9.7 Sample Size Considerations  
 
 Sample Size .  A minimum of 24 subjects will be  randomized .  Desmetramadol  and tramadol are 
closely related chemicals and are therefore expected to have a similar intra -patient coefficient of variation 
and food -effect.  Published studies indicate a ~15% intra -subject coefficient of variation for immediate 
release tramadol  (Najib 2009 , ESP_Pharma_Limited 2010 , Dhanure 2013 ), and the Ultram label indicates 
that “oral administration of U ltram with food does not significantly affect its rate or extent of absorption, 
therefore, Ultram can be administered without regard to food.”  
 
  Intra -Subject CV   
 Najib 2009  
(N=24)  ESP Pharma Limited 2010  
(N=18)  Dhanure 2013  
(N=35)  
AUC (0-t) 12% 12% 5.6 
AUC (inf) 12% 11% 6.3 
Cmax 12% 15% 15.0 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
27 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   Using a conservative estimate of 20% for the intra -subject coefficient of variation  (CV)  of 
desmetramadol , and a 5% level of significance, a sample size of 24 subjects is considered sufficient to 
provide 89.6% power  (essentially 90% power)  to establish dose -proportionality and absent food effect , 
assuming no multiplicity and a fed/fasting ratio of 0.95 and a 5% deviation  from 1 for the slope β in dose  
proportionality .  Based on a study drop-out rate of ~30% in the Ultram label , up to 8 additional subjects 
(alternates) might be randomized to enable a per protocol population of 24 subjects  with blood draws at 
each treatment period  (based on our completed phase 1 study in 43 subjects, dropouts are unlikely to 
exceed 5%; see Section 1.2.2 ). 
 
 Sensitivity Analysis .  ICH E9, “It is important to investigate the sensitivity of the sample size estimate 
to a variety of deviations from these assumptions and this may be facilitated by providing a range of 
sample sizes appropriate for a reasonable range of deviations from ass umptions.”  Generally power is set 
to at least 80% in BE studies, and a minimum of 12 evaluable subjects should be included in any BE 
study (FDA 2001 ).  However, even with a power of 80%, 1 in 5  studies will fail by mere chance alone, 
and thus higher power is preferable.  Based on the assumption s above  of a 5% deviation  from 1 for  the 
slope β in dose  proportionality  and a 20% intra -subject CV, 20 subjects provide  at least 80% power and 
24 subject s provide nearly 90% power (table below) . 
 
  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
28 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.       N*     
 12 14 16 18 20 22 24 26 28 
5% β deviation           
 CV          
 15% 80.0%   90+%       
 20%   73.5%  79.1%  83.5%   89.6%  90+%   
 25%        78.0%  80.0%  
          
10% β deviation           
 CV          
 15%     80+%     
 20%       70.0%   <80%  
 25%         <<80%  
*Note that a balanced four -sequence Williams’ design requires an N evenly divisible by 4.  
 
 If the intra -subject CV is actually closer to the published value for tramadol of 15%, then as few as 12 
subjects provide at least 80% power and 16 subjects provide at least 90% power (see table).  On the other 
hand, if the intra-subject CV is much worse at 25%, then the planned enrollment of 24  subjects fails to 
provide the minimum threshold of 80% power.  Likewise, if the deviation  from 1 in  the slope β is 10% 
instead of 5%, then only a 15% intra -subject CV and 20 enrolled subjects will provide the minimu m 
desired power of 80%.  Higher intra-subject CVs of 20% and 25% both fail to provide at least 80% power 
with this degree of deviation in β, even with as many as 28 subjects.  Based on this sensitivity analysis 
and the  small  (6-15%) actual intra -subject  CV for the closely related molecule tramadol , the planned 
enrollment of 24 subjects prov ides a comfortable margin of power should the already conservative 
estimates of 20% int ra-subject CV  and 5% β deviation prove  correct or  even  slightly  larger .   
 
9.8 Maintena nce of Trial Randomization List 
 
 Syntrix  and the site pharmacist , investigator or investigator designee  will maintain the randomization 
list. 
 
9.9 Subject  Enrollment and Follow -Up 
 
 The total number of subjects who complete the PK analysis  in all 4 Periods  is targeted to be 24.  The 
total duration of accrual is 4 month s, and duration from first patient enrolled until final subject contact is 
about 6 weeks .   
 
9.10 Safety Review  
 
 No formal interim statistical analyses will be performed for safety.   
 
9.11 Final Analysis Plan  
 
 A formal statistical analysis plan will be developed and finalized prior to data analysis.  
 
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
29 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  10 ADMINISTRATIVE PROCEDURES  
 
10.1 Institutional Review Board Approval  
 
 The protocol for this study has been designed in accordance with Good Clinical Practice and ICH E6. 
The review of this protocol by the Institutional Review Board (IRB) and the performance of all aspects of 
the study, including the methods used for obtaining in formed consent, must also be in accordance with 
principles codified in Title 21 Code of Federal Regulations (CFR) Part 50 Protection of Human Subjects 
and Part 56 Institutional Review Boards.  
 
 The Investigator will be responsible for preparing and submitt ing documents to the relevant IRB , and 
obtaining written IRB approval for this study.  The approval will be obtained prior to study initiation . 
 
10.2 Informed Consent  
 
 A study informed consent will be obtained from each subject.  The Investigator or designee  will 
explain the nature of the investigation and the risks involved to each subject prior to enrollment, and will 
obtain written informed consent. The subject will also be informed that he/she is free to voluntarily 
withdraw from the study at any time.  
 
10.3 Direct Access to Source Data/Documents , Study Monitoring , Data Collection  
 
 The Investigator will allow representatives of Syntrix  (or their designee) to periodically monitor , at 
mutually convenient times during and after the study, all CRFs and corresponding source documents for 
each subject. It is important that the Investigator or staff is available at these visits. The monitoring visits 
provide Syntrix  with the opportunity  to evaluate the progress of the study, to verify the accuracy and 
completeness of CRFs, to resolve any inconsistencies in the study records, as well as assuring that all 
protocol requirements, applicable regulations, and Investigator's obligations are bei ng fulfilled. The 
Investigator must maintain all source documents, i.e., all information, original records of clinical findings, 
observations, or other activities necessary for the reconstruction and evaluation of the trial.  Examples of 
these original doc uments and data records include, but are not limited to clinical charts, laboratory notes, 
pharmacy dispensing records, and subject files and records kept at the pharmacy, at the laboratories, and 
other medico -technical departments involved in the clinical  trial), for possible review.   The investigational 
site will pro vide direct access to all trial -related source documents, other documents, and reports for the 
purpose of monitoring and auditing by Syntrix and regulatory authorities.    
 
 The Syntrix  represe ntative  will record the date of each monitoring visit together with a summary of 
the status and progress of the study. Proposed actions will be confirmed with the Investigator in writing.   
Telephone contact will be made as necessary during the data collect ion period and during the data and 
report writing periods . 
 
 Celerion standard CRFs will be supplied. CRFs are produced, stored electronically, and are 
available to the designated study team members. Each CRF is reviewed and signed by the PI. The final 
signed CRFs are provided to the Sponsor in the format as decided upon between Celerion and the Sponsor 
(e.g., CD, flashdrive, SFTP). This will be documented in the DMP (if applicable).   
   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
30 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   If CRF entries are modified, the initials of the associate making th e change as well as the date and 
reason for the change will be captured in an electronic audit trai l.  The clinical monitors will verify that 
the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance 
with the  protocol and the applicable regulatory requirements.  
 
Standard operating procedures are available for all activities performed at Celerion relevant to the quality 
of this study. Designated personnel of Celerion will be responsible for implementing and mai ntaining 
quality assurance (QA) and quality control systems to ensure that the study is conducted, and that data are 
generated, documented and reported in compliance with the study protocol, and GCP requirements as well 
as applicable regulatory requirement s and local laws, rules and regulations relating to the conduct of the 
clinical study.  
All clinical data will undergo a 100%  quality control check prior to clinical database lock. Edit checks are 
then performed for appropriate databases as a validation rou tine using SAS® or comparable statistical 
program to check for missing data, data inconsistencies, data ranges, etc. Corrections are made prior to 
database lock.  
The Clinical Study Report will be audited by the QA department and the QA audit certificate wi ll be 
included in the study report.  
10.4 DATA ANALYSIS  
 
Data will be handled and processed according to Celerion SOPs, which are written based on  
the principles of GCP. A brief description of the statistical analysis is included below,  
detailed methodology for all summary and statistical analyses of the data collected in this  
trial will be documented in a statistical analysis plan (SAP) prepared by Celerion and agreed  
upon by the Sponsor. The SAP may modify the plans outlined in the protocol; however, any  
major modifications of the primary endpoints and/or their analysis will also be reflected in a  
protocol amendment. If deemed appropriate, additional statistical analyses other than those  
described in this section may be performed and included in the plan.  
 
10.5 Modification  of the Protocol  
 
 No deviations from the protocol are permitted . Syntrix  may approve minor exceptions on a case -by-
case basis. If modification of the protocol is necessary, the modification must be initiated and confirmed 
in writing by Syntrix , and the Investigator will inform the IRB and not institute the modification  until 
approved by the IRB.  
 
10.6 Protocol Deviation(s)  
 
 A protocol deviation is any noncompliance with the clinical trial protocol or Good Clinical Practice.  
Syntrix’s Medical Direc tor should be consulted if there is uncertainty as to whether a protocol deviation 
has occurred.  The noncompliance may be either on the part of the subject, the investigator, or the study 
site staff.  As a result of deviations, corrective actions are to b e developed by the site and implemented 
promptly.  Protocol deviations will be recorded by the site and included in the final study report.  It is the 
responsibility of the site to use continuous vigilance to identify and report deviations.  Protocol devia tions 
must be sent to the IRB per their guidelines.   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
31 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.  10.7 Departure from the Protocol  
 
 When an emergency involving an individual occurs a departure from the protocol may be required.  
This protocol departure will be limited to this individual  emergency.  The Investigator , or other physician s 
in attendance , in such an emergency will, if circumstances and time permit, contact Syntrix immediately 
by telephone. The protocol deviation forms  will completely describe the departure from the protocol and 
state the rea sons for such departure. The IRB must be notified immediately if the departure from the 
protocol affects the safety or rights of the subject .   
 
10.8 Suspension of the Study  
 
 If safety concerns arise during the study, the Sponsor may suspend, amend or terminat e the study .  
Furthermore, if the study  is suspended , the Sponsor may resume the study once the safety concern is 
resolved.  
 
10.9 Study Termination by the Sponsor  
 
 Syntrix retains the right to terminate the study for any cause, suspending subject enrollment an d 
removing all investigational products and related study materials from the study site at any time. Specific 
instances, which may precipitate such termination at a site, are as follows:  
 
• Deviation from protocol requirements.  
 
• Inaccurate or incomplete data  recording on a recurrent basis.  
 
• Unauthorized use of investigational products.  
 
• Delinquent fulfillment of obligation on the part of the Investigator with regard to adverse 
reaction reporting, unacceptable subject enrollment, or other responsibilities as outlined in this 
protocol.  
 
10.10  Use of Information and Publications  
 
 Publication of the results of this study is encouraged subsequent to full data analysis.  No part of the 
results of the study, or any of the information provided by the S ponsor to the Investigator for the purposes 
of performing the study, will be published, or passed on to a third party, without prior review by the 
Sponsor.  The Investigator, or anyone else working on the study, will submit all proposed publications, 
paper s, abstracts or other written materials related to the Study, or an outline of any proposed oral 
presentation with respect thereto, to the Sponsor at least one month prior to (i) submission of such written 
materials for publication, or (ii) any proposed or al disclosure to a third party.  
 
 The Sponsor shall have the right to comment on such written material or outline; such comments shall 
be considered in good faith by the Investigator in determining the final form of disclosure.  In the event 
patentable mat erial is identified in the data, the Sponsor may delay publication for up to six months to 
submit the appropriate patent applications.  Notwithstanding any of the above, the Investigator or anyone 
else working on the Study may not include any confidential information in any such publication or 
disclosure.  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
32 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted 
without prior written authorization from Syntrix Biosystems, Inc.   
 The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a 
trials -registration policy as a condition for publication.  This policy requires that clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library 
of Medicine.  The ICMJE defines a clinical trial as any research project that prospectively assigns human 
subjects to intervention or comparison group s to study the cause -and-effect relationship between a 
medical intervention and a health outcome.  Studies designed for other purposes, such as to study 
pharmacokinetics or major toxicity (e.g., Phase 1 trials), would be exempt from this policy.  Syntrix w ill 
register this trial in a public trials registry .     
 
 The Investigator is obliged to provide the Sponsor with complete test results and all data derived from 
the study.  Only the Sponsor may make information obtained during and from the study availabl e to 
regulatory agencies, except as required by regulation.  
 
10.11  Record Retention  
 
 The Investigator or Investigative site  must  retain the clinical study until a minimum of two years 
following the last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least two years have elapsed since the formal 
discontinuation of clinical development of the study agent.  Syntrix Biosystems will notify sites when 
records can be de stroyed.  In the event this information is not communicated to the sites, permission must 
be obtained from Syntrix Biosystems before records can be destroyed . 
 
10.12  Exclusion of Minorities, and Children (Special Populations)  
 
 Children and subjects less than 19 years of age are excluded from this phase 1 study.  Thus, the study 
will not enroll children, prisoners, or other vulnerable populations.  The study is therefore exempt from 45 
CFR 46 Subparts B, C and D.   
 
 Minorities and underinsured person s are encour aged to participate .  Since the sponsor pays for the 
study medication, lab tests and examination costs, there are no impediments to anyone’s participation in 
the study.   
  
10.13  Subject  Confidentiality  
 
 Subject confidentiality will be maintained, and neither full names nor social security numbers will be 
entered into the database.  Subject  confidentiality will be strictly held in trust by the participating 
Investigators  and their staff, and the Sponsor an d their representative s.   
 
 The study protocol, documentation, data and all other information generated will be held in strict 
confidence.  No information concerning the study or the data will be released to any unauthorized third 
party, without prior w ritten approval of the Sponsor.  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
33 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted without 
prior written authorization from Syntrix Biosystems, Inc.  Appendix A: Schedule of Procedures/Evaluations  
1 Interim history and sympt om driven physical examinations.  Do not include height or BMI calculation.  
2 Vital signs  (blood pressure, pulse, respiratory rate, and temperature)  will be obtained in the sitting position at screening, on 
clinical pharmacology un it admission day, before each study drug dose, 30 -60 minutes after study drug administration, and before 
discharge.  If the initial RR assessment indicates <10/min, then the RR assessment will be repeated with the rate determeined over 
60 seconds.  
3 Complet e blood count includes: WBCs, platelets, RBCs, hemoglobin, hematocrit .  Differential includes % and absolute number 
of: neutrophils (all phases of development), lymphocytes (typical and atypical), monocytes, eosinophils, and basophils.   Urinalysis 
includes : appearance, and by dipstick pH, specific gravity, protein, sugar (glucose), keytones, bilirubin, leukocyte esterase or 
nitrites, blood , urobilinogen . If on the dipstick protein, leukocyte esterase or nitrites, or blood is positive, then a microscopic 
analysis of the urine will be performed.  
4 Substances to be tested inclue: amphetamines, barbituates, benzodiazepines, opiates, cocaine, cannabinoids, and ethanol.  
5 Female subjects only . At screening obtain a serum pregnancy test.  At check -in (Day -1) obtain a urine pregnancy test.  
6 See Appendix A Auxilliary  that follow s this page for collection details .  
7 On day 11 safety lab blood collections may be done at time of 24 hour PK blood s pecimen collection; other procedures should be 
done around the time of the final PK blood specimen collection prior to discharge.    
8 If a subject terminates early , then Day 11 procedures , as noted in Appendix  A, should be completed before subject terminat es 
from the study.   
  Procedure  Screen  
Days  Day Of Study  
-31 
to 
-1 -1 1 2 3 4 5 6 7 8 9 10 117,8 
In-CPU Stay   X X X X X X X X X X X X 
Randomization    X           
Study Drug Administration    X   X   X   X  
Clinical               
 Informed Consent  X             
 Review  Contraception Requirements  with 
 female subjects  X X           X 
 Medical History  X X1            
 Physical Exam include height, weight, BMI 
 calculation.  X X1            
 Vital signs2 X X X   X   X   X X 
 ECG  X             
 Concomitant Medications   X X X X X X X X X X X X 
 Adverse Events    X X X X X X X X X X X 
Safety Lab Tests               
 CBC with Differential3 X            X 
 BUN, creatinine, AST, ALT ,  alkaline 
 phosphatase,   total bilirubin,  albumin, total 
 protein , sodium, potassium, chloride, 
 bicarbonate, calcium, glucose (random),  X            X 
 PT, PTT  X             
 HIV, Hepatitis B & C Serology  X             
 UA3 X             
 Urine Test for Substances of Abuse4 X X            
 Pregnancy Test5 X X            
Samples for Pharmacokinetic Analysis6   X X  X X  X X  X X 
Discharge              X 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
34 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted without 
prior written authorization from Syntrix Biosystems, Inc.   
Appendix A  Auxiliary : Detailed Pharmacokinetic Sampling Schedule  
 
Days 1 -2, 4-5, 7-8 and 10 -11 (urine only for 30 mg fasted subjects) . 
 
Blood  collection1 
(+)-M1, ( -)-M1, (+) -M5, (-)-M5 Urine  collection2 
M1 and M5 achiral , 24 hr creatinine  Blood collection3 
Creatinine  for 24 hr CL CR 
pre-dose collect pre-dose void  (negative control)   
0.5 hr (+/- 5 minutes)    
1.0 hr  (+/- 10 minutes )   
1.5 hr (+/- 10 minutes)    
2.0 hr (+/- 10 minutes)  0.0 to 2.0 hour interval   
2.5 hr (+/- 10 minutes)    
3.0 hr (+/- 10 minutes)    
3.5 hr (+/- 10 minutes)    
4.0 hr (+/- 15 minutes)  2.0 to 4.0 hour interval   
6.0 hr (+/- 15 minutes)  4.0 to 6.0 hour interval   
8.0 hr (+/- 15 minutes)  6.0 to 8.0 hour interval   
12.0 hr (+/- 15 minutes)  8.0 to 12.0 hour interval  12.0 hr (+/- 15 minutes)  
16.0 hr (+/- 15 minutes)  12.0 to 16.0 hour interval   
24.0 hr (+/- 15 minutes)  16.0 to 24.0 hour interval   
32.0 hr (+/- 15 minutes)  24.0 to 36.0 hour interval   
 
Footnotes:  
 
1.  Collect  in K2 EDTA tubes .  Centrifuge, split and freeze two duplicate 1 mL aliquots for each time point.  
2.  Record urine volume collected in each interval.  Freeze two duplicate 1 mL aliquots from each interval.  
3.  Collect blood at 12 hours (mid -point of 24 hour urine collection) in order to compute 24 hour creatinine 
clearance.  
4.  After all urine aliquots are obtained from the intervals in  the first 24 hours, pool urine collected between 0.0 
and 24.0 hours and mix.  Take  two duplicate 1 mL aliquots and use one to quantitate urine creatinine , and freeze 
the other one as a backup .  Creatinine clearance (CL CR) may be computed w ith the urine level of creatinine in 
24 hours  of urine and the blood level of creatinine measured at the time midpoint (i.e., at 12 hours).1  The 
clearance mechanism of M1 and M5 is less likely to involve  only glomerular filtration and no  renal tubular 
secretion or absorptio n if CL M1 and CL M5 resemble CL CR across doses.  
 
 
 
 
 
1 One online calculator is at:  
 http://www -users.med.cornell.edu/~spon/picu/calc/crclcalc.htm  pool4 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
35 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Appendix B.  Calculation of Selected Inclusion Criteria  
 
1.  Inclusion Criteria:  GFR Estimate by Cockcroft -Gault Formula  
 
     GFR = [(140 – age) x weight]  
      72 x SCR  
 
where,   age is in years  
   weight is in kg  
   serum creatinine (S CR) is in mg/dL.  
   GFR is ml/min  
                                
in females, the result is multiplied by 0.85 (Cockcroft 1976 ).  The Cockcroft -Gault value is not 
adjusted for body su rface area (BSA), and in this protocol must be equal to or greater than 60 
ml/min.  An online Cockcroft -Gault calculator is available at: http://nephron.com/cgi -
bin/CGSI.cgi  . 
 
 
2.  Inclusion Criteria:  Body Mass Index (BMI)  
 
    BMI = (Weight in Pounds x 703)/(Square of Height in Inches)  
 
Examples : 
 
Weight = 188 lbs    Weight = 258 lbs  
Height = 72 inches (6 feet)   Height = 72 inches (6 feet)  
BMI = 25.5     BMI = 35.0  
 
Online  BMI calculators are also available (e.g. http://www.nhlbisupport.com/bmi/bmicalc.htm  ). 
 
Clinically accepted guidelines note that a BMI from 18.5 -24.9 is n ormal; 25.0 to 29.9 is 
overweight; a BMI of greater than or equal to 30.0 is obese; and a BMI of greater than or equal 
to 35.0 is morbidly obese.   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
36 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted without prior written authorization from Syntrix 
Biosystems, Inc.   
Appendix C: Toxicity Grading Scale for Clinical Laboratory Values1 
 
 
1 = FDA  Guidance for  Industry  Toxicity Grading  Scale for  Healthy Adults  Enrolled in Preventive Vaccine Clinical  Trials,  2007.  ULN=upper  limit of normal;  LLN=lower  limit of 
normal.  Parameter  Normal  Range  (Grade  0) Grade  for Abnormal  Results  (Value  or Change  from  Reference)  1 
 Normal Values  Mild  (Grade  1) Moderate  
(Grade  2) Severe  
(Grade  3) Potentially  Life- 
threatening  (Grade  4) 
BUN  (mg/dL)   23-26 27-31 >31 Requires dialysis  
Creatinine  (mg/dL)   > ULN  - 1.7 1.8 - 2.0 2.1 - 2.5 > 2.5 or requires  dialysis  
ALT  (SGPT)  (U/L)   > ULN  - 2.5 x ULN > 2.6 - 5.0 x ULN > 5.1 - 10 x ULN > 10 x ULN 
AST  (SGOT)  (U/L)   > ULN  - 2.5 x ULN 2.6 - 5.0 x ULN 5.1 - 10 x ULN > 10 x ULN 
PT (prothrombin time)   >ULN – 1.2 x ULN  1.11 – 1.20 x ULN  1.21 – 1.25 x ULN  > 1.25 ULN  
PTT (partial 
tthromboplastin time)   >ULN – 1.2 x ULN  1.21 – 1.4 x ULN  1.41 -1.5 x ULN  > 1.5 x ULN  
WBC  (K/µL  or 109/L)  > ULN  - 15.0 
2.5 - < LLN > 15.0 - 20.0 
≥ 1.5 - < 2.5 > 20.0 - 25.0 
≥ 1.0 - < 1.5 > 25.0 
< 1.0 
Hemoglobin  (g/dL)   M: 12.5 - < LLN  
F: 11 - < LLN M: 10.5 - 12.4 
F: 9.5 - 10.9 M: 8.5 - 10.4 
F: 8.0 - 9.4 < 8.5 
< 8.0 
Platelet  count  (K/µL  
or 109/L)  100 - < LLN 50 - 99  < 50   
 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
37 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Appendix D: Toxicity Grading Scale for Clinical AEs ¹ 
VITAL  SIGNS  
 Grade 1 
Mild Grade 2 
Moderate  Grade 3 
Severe Grade 4  
Potentially  Life-threatening  
Fever:  oral (˚C)  
(˚F) 38.0 - 38.4 
100.4  - 101.1 38.5 - 38.9 
101.2  - 102.1 39.0 - 40.0 
102.2 - 104 > 40.0 
> 104 
Tachycardia  - bpm 101 - 115 116 - 130 >130  ER visit or hospitalization  for 
arrhythmia  
Hypertension  
(systolic)  mm Hg  141 - 150 151 - 155 >155  ER visit or hospitalization  for 
malignant  hypertension  
Hypertension  
(diastolic)  mm Hg 91 – 95 96 - 100  >100  ER visit or hospitalization  for 
malignant  hypertension  
Hypotension  
(systolic)  mm Hg  85 – 89 80 - 84  <80  ER visit or hospitalization  for 
hypotensive shock 
SYSTEMIC  (GENERAL)  
Nausea/Vomiting  No interference with  
activity  or 1 - 2 episode in  
24 hours Some interference  with 
activity  or >2 episodes  in 
24 hours Prevents daily  activity  or 
requires outpatient  IV 
hydration  ER visit or hospitalization  for 
hypotensive shock 
Diarrhea  2-3 loose  stools  in 24 
hours 4-5 loose  stools  in 24 
hours > 5 watery  stools in  24 
hours or  outpatient  IV 
hydration  Requiring  significant/urgent  
medical  care or hospitalization  
Headache  No interference with  
activity  Repeated  use of 
non-narcotic pain reliever  
> 24 hours or  some  
interference  with activity  Significant;  use of 
narcotic  pain reliever  or 
prevents  daily  activity  Requiring  significant/urgent  
medical  care or hospitalization  
Malaise/fatigue,  
muscle pain,  chills,  
anorexia (loss of 
appetite),  self- 
reported  symptoms  of 
‘fever’  (no 
temperature taken)  No interference with  
activity  Some interference  with 
activity  Significant;  prevents  
daily  activity  Requiring  significant/urgent  
medical  care or hospitalization  
Allergic  reaction  Pruritus without  rash Localized  urticaria (rash)  Generalized  urticaria;  
angioedema  Requiring  significant/urgent  
medical  care or hospitalization  
Hives  (urticaria)  Urticarial  lesions covering  
<10%  BSA;  topical  
intervention  indicated  Urticarial  lesions covering  
10 -30% BSA;  oral 
intervention indicated  Urticarial  lesions  
covering >30%  BSA;  IV 
intervention  indicated   
Illness  or clinical  
adverse event  No interference with  
activity.  Some interference  with 
activity  but does not 
require  medical  
intervention  Prevents daily  activity  
and requires  medical  
intervention  Requiring  significant/urgent  
medical  care or hospitalization  
1 = FDA  Guidance for  Industry  Toxicity Grading  Scale for  Healthy Adults  Enrolled in Preventive Vaccine Clinical  Trials,  2007.  
 
  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
38 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  References  
 
Bamigbade, T. A., et al. (1997). "Actions of tramadol, its enantiomers and principal metabolite, 
O-desmethyltramadol, on serotonin (5 -HT) efflux and uptake in the rat dorsal raphe nucleus." Br 
J Anaesth  79(3): 352 -356. 
CBER (September 2007). Guidance for industry: Toxicity grading scale for healthy adult and 
adolescent volunteers enrolled in preventive vaccine clinical trials, U.S. Department of Health 
and Human Services, Food and Drug Administration.   
Cockcroft, D. W.,  et al. (1976). "Prediction of creatinine clearance from serum creatinine." 
Nephron  16(1): 31 -41. 
Desmeules, J. A., et al. (1996). "Contribution of monoaminergic modulation to the analgesic 
effect of tramadol." Br J Clin Pharmacol  41(1): 7 -12. 
Dhanure, S.,  et al. (2013). "Bioequivalence study of tramadol + paracetamol (37.5 + 325 mg) in 
healthy human volunteers in fasting condition." IJPSDR  5(4): 179 -183. 
Driessen, B., et al. (1992). "Interaction of the central analgesic, tramadol, with the uptake and 
relea se of 5 -hydroxytryptamine in the rat brain in vitro." Br J Pharmacol  105(1): 147 -151. 
Driessen, B., et al. (1993). "Effects of the central analgesic tramadol on the uptake and release of 
noradrenaline and dopamine in vitro." Br J Pharmacol  108(3): 806 -811. 
Enggaard, T. P., et al. (2006). "The analgesic effect of tramadol after intravenous injection in 
healthy volunteers in relation to CYP2D6." Anesth Analg  102(1): 146 -150. 
ESP_Pharma_Limited (2010). Public Assessment Report, Scientific Discussion.  Applican t: ESP 
Pharma Limited.  Tradoloris 50 mg, hard capsules Tramadol ESP PHARMA 50 mg, hard 
capsules (Tramadol hydrochloride).  FR/H/402/01/DC and FR/H/403/01/DC.  September 2010., 
Agence francaise de securite sanitaire des product de sante (afssaps).   
FDA (2 001). "FDA Guidance for Industry.  Statistical Approaches to Establishing 
Bioequivalence.  January 2001.".  
Grond, S., et al. (2004). "Clinical pharmacology of tramadol." Clin Pharmacokinet  43(13): 879 -
923. 
Hagelberg, N. M., et al. (2013). "Ticlopidine inhi bits both O -demethylation and renal clearance 
of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the 
ticlopidine -tramadol interaction." Eur J Clin Pharmacol  69(4): 867 -875. 
Ide, S., et al. (2006). "Mu opioid receptor -depen dent and independent components in effects of 
tramadol." Neuropharmacology  51(3): 651 -658. 
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
39 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Kayser, V., et al. (1991). "Effects of the analgesic agent tramadol in normal and arthritic rats: 
comparison with the effects of different opioids, including toleran ce and cross -tolerance to 
morphine." Eur J Pharmacol  195(1): 37 -45. 
Kayser, V., et al. (1992). "Evidence for a noradrenergic component in the antinociceptive effect 
of the analgesic agent tramadol in an animal model of clinical pain, the arthritic rat." Eur J 
Pharmacol  224(1): 83 -88. 
Kirchheiner, J., et al. (2008). "Effect s of the CYP2D6 gene duplication on the pharmacokinetics 
and pharmacodynamics of tramadol." J Clin Psychopharmacol  28(1): 78 -83. 
Najib, N. M., et al. (2009). "Effect of truncated AUC method on drug bioequivalence in 
humans." J Bioequiv Availab  1(4): 112 -114. 
Poulsen, L., et al. (1996). "The hypoalgesic effect of tramadol in relation to CYP2D6." Clin 
Pharmacol Ther  60(6): 636 -644. 
Preskorn, S. H., et al. (2013). "Cytochrome P450 2D6 phenoconversion is common in patients 
being treated for depression: implicat ions for personalized medicine." J Clin Psychiatry  74(6): 
614-621. 
Raffa, R. B. (2008). "Basic pharmacology relevant to drug abuse assessment: tramadol as 
example." J Clin Pharm Ther  33(2): 101 -108. 
Raffa, R. B., et al. (2012). "Mechanistic and functional differentiation of tapentadol and 
tramadol." Expert Opin Pharmacother  13(10): 1437 -1449.  
Raffa, R. B., et al. (1992). "Opioid and nonopioid components independently contribute to the 
mechanism of action of tramadol, an 'atypical' opioid analgesic." J Pharm acol Exp Ther  260(1): 
275-285. 
Rani, S. (2007). "Bioequivalence: Issues and perspectives." Indian J Pharmacol  39(5): 218 -225. 
Sansone, R. A., et al. (2009). "Tramadol: seizures, serotonin syndrome, and coadministered 
antidepressants." Psychiatry (Edgmont)  6(4): 17 -21. 
Smith, B. P., et al. (2000). "Confidence interval criteria for assessment of dose proportionality." 
Pharm Res  17(10): 1278 -1283.  
Stamer, U. M., et al. (2003). "Impact of CYP2D6 genotype on postoperative tramadol analgesia." 
Pain 105(1-2): 231 -238. 
Stamer, U. M., et al. (2007). "Concentrations of tramadol and O -desmethyltramadol enantiomers 
in different CYP2D6 genotypes." Clin Pharma col Ther  82(1): 41 -47. 
SYN -PAIN -115 (2011). Single -dose oral PK of Omnitram (20 mg M1 SR102 tablet) in healthy 
male.  February 28, 2011.  
Protocol version 1.2    Syntrix -Omni -PAIN -103   11 May 2020  
40 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Tirkkonen, T., et al. (2004). "Drug interactions with the potential to prevent prodrug activation as 
a common source of  irrational prescribing in hospital inpatients." Clin Pharmacol Ther  76(6): 
639-647. 
Wang, G., et al. (2006). "Effect of the CYP2D6*10 C188T polymorphism on postoperative 
tramadol analgesia in a Chinese population." Eur J Clin Pharmacol  62(11): 927 -931. 
Yanarates, O., et al. (2010). "Spinal 5 -HT7 receptors play an important role in the 
antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O -
Desmethyltramadol, via activation of descending serotonergic pathways." Anesthesiology  
112(3): 696-710. 
 
 